Section 3 of 6
Product information and disease description
377 evidence topics · 152 sources
Product description
Phase of product development
Regulatory status: Submission planned; BLA planned for 2027
Launch
No evidence found.
Development phase: phase 3, with phase 3 treatment continuing to 52 weeks
Additional phase 3 results anticipated in February 2027
Phase 3 topline results reported in September 2026
Phase 3 enrollment completed in February 2026
Phase 3 trials initiated in July 2024
Phase 2 study: first participant dosed in June 2022
Subcutaneous formulation phase 1 study in healthy volunteers: first cohort dosed in September 2021
Phase 1b study in chronic spontaneous urticaria: first participant dosed in October 2020
Development in other indications: cold urticaria, symptomatic dermographism, atopic dermatitis, prurigo nodularis, and eosinophilic esophagitis
FDA expedited program designations for chronic spontaneous urticaria
No evidence found.
Patent protection: U.S. composition of matter patent with estimated expiry in 2034
Phase 3 topline timing, July 2026 to August 2026, superseded in September 2026
Phase 3 topline timing, February 2026 to June 2026, superseded in July 2026
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Celldex Therapeutics
International nonproprietary name and description
| Field | Quoted record |
|---|---|
| INN list | “Proposed INN: List 125” |
| Latin name | “barzolvolimabum” |
| English name | “barzolvolimab” |
| Description | “extracellular domain], monoclonal antibody” |
| Expression system | “produced in Chinese hamster ovary (CHO) cells, glycoform alfa” |
| Functional class | “immunomodulator” |
Proprietary name
No evidence found.
Therapeutic class: humanized IgG1 kappa anti-KIT monoclonal antibody
Dosage forms and strengths
Dosage form: 1 mL pre-filled syringes for subcutaneous administration
Strength and concentration per pre-filled syringe
No evidence found.
Intravenous formulation in phase 1 studies and subcutaneous formulation for phase 2
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
No evidence found.
Indication
Proposed indication studied in phase 3: adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment
Prior biologic experience permitted in the phase 3 trials
Pharmacology
Mechanism of action
Humanized monoclonal antibody that binds KIT and blocks SCF binding and KIT dimerization
Allosteric inhibition through the membrane-proximal dimerization domains of KIT
“CDX‐0159 is a humanized IgG1/κ monoclonal antibody with a modified Fc domain that was derived from CDX‐0158, a predecessor anti‐KIT antibody with an unmodified IgG1/κ backbone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The antibody was developed from mice immunized with the membrane proximal dimerization domains (Ig 4 and 5) of human KIT (huKIT‐D4D5), which are required for KIT activation by SCF but are not directly involved in ligand binding.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CDX‐0159 bound to KIT naturally expressed in the surface of megakaryoblastic leukemia M‐07e cells with an EC50 of 153 ± 22 pM (Figure 1B), and completely blocked binding of fluorescently labeled SCF to M‐07e cells with an IC50 value of 118 ± 6 pM (Figure 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CDX‐0159 allosterically blocks binding of SCF to KIT, which may result in an elevation of SCF plasma levels from accumulating unbound SCF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selectivity and inhibition of SCF-dependent KIT phosphorylation and mast cell degranulation
“Furthermore, CDX‐0159 bound specifically to KIT but not to other related type‐III receptor tyrosine kinases (Figure S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, titration of CDX‐0159 on CHO cells stably transfected to express human KIT (CHO‐KIT) inhibited SCF‐dependent KIT phosphorylation (Figure 1D) with an IC50 of 232 ± 4 pM, or 2–3 orders of magnitude more potently than FDA‐approved KIT‐targeting TKIs imatinib, pexidartinib, and avapritinib (IC50 = 931 ± 78 nM, 87 ± 7 nM, and 175 ± 59 nM, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this assay, CDX‐0159 titration fully inhibited SCF‐dependent MC degranulation (IC50 = 650 ± 88 pM) (Figure 1F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fc substitutions that abolish effector function and reduce clearance
“To eliminate the potential for FcγR crosslinking and effector functions, we engineered 3 amino acid substitutions (L234A/L235Q/K322Q) in the Fc region of CDX‐0158 predicted to abolish FcγR binding and expected to similarly impact C1q receptor binding.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, we also incorporated a set of modifications (M252Y/S254T/T256E)—herein named YTE—that increase the binding affinity for the neonatal Fc receptor (FcRn) which enhances the pharmacokinetic (PK) properties of the mAb by reducing the rate of in vivo clearance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Taken together, these data demonstrate that the Fc modifications in CDX‐0159 effectively abolish Fc‐dependent effector function and agonist activity leading to MC degranulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KIT expression on mast cells and on other cell types
“The KIT (c‐KIT/CD117) receptor tyrosine kinase and its only ligand stem cell factor (SCF) are master regulators of MC biology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“KIT is highly expressed throughout the life of a MC and is also expressed in hematopoietic stem cells, melanocytes, interstitial cells of Cajal, germ cells, and a subset of taste receptor cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mast cell depletion as the hypothesized basis of benefit in CSU
“Barzolvolimab—a monoclonal anti‐KIT antibody—depletes MCs by inhibiting activation of KIT by stem cell factor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab, as a potent inhibitor of SCF‐dependent KIT activation in cells, is hypothesized to provide therapeutic benefit in patients with CSU by decreasing the number of MCs and their activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results support the anti‐KIT mechanism of action for treating CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had similar symptom improvement irrespective of prior omalizumab use, suggesting that barzolvolimab can help improve urticaria symptoms regardless of whether IgE is the underlying trigger.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The observed AEs in barzolvolimab‐treated patients reflect KIT‐mediated toxicities and were reversible, consistent with the expected effects of KIT inhibition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Wild-type and KITD816V mast cell models: apoptosis and SCF-enhanced IgE-mediated activation
“We established and characterized primary-like human MC models, including isogenic human induced pluripotent stem cell-derived WT and heterozygous KITD816V MCs, peripheral CD34+ stem cell-derived MCs, and HMC-1.2 cell line.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab induced dose-dependent apoptosis and inhibited stem cell factor-induced KIT signaling in WT MCs, but it had no effect on mutant MC viability or signaling.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, barzolvolimab effectively suppressed stem cell factor-enhanced IgE-mediated MC activation across all primary-like models, including KITD816V MCs, as evidenced by reduced β-hexosaminidase release and CD63 expression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This inhibitory effect occurred at low nanomolar concentrations and was independent of cytotoxicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cold urticaria and symptomatic dermographism: skin mast cells as the effector cells
Eosinophilic esophagitis: mast cell depletion without improved clinical outcomes
Prurigo nodularis: mast cell depletion without improvement in itch or skin lesions
Pharmacodynamics
Serum tryptase and plasma SCF in CSU: phase 1b, intravenous dosing every 4 or 8 weeks
“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lowest dose (0.5 mg/kg) showed transient improvements in clinical activity that correlated with partial tryptase suppression, SCF increases, and subsequent recovery prior to the following dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum tryptase depletion in the phase 2 CSU trial
Baseline serum tryptase in CSU compared with healthy participants, and response by baseline tryptase: phase 2 post hoc analysis
Tryptase recovery during the 24-week follow-up period of the phase 2 CSU trial
Serum tryptase and plasma SCF in healthy volunteers: single intravenous doses
“A single ascending dose (0.3, 1, 3, and 9 mg/kg), double‐blinded placebo‐controlled phase 1a human healthy volunteer study (n = 32) was conducted to evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX‐0159.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tryptase reduction was manifest in all subjects dosed with CDX‐0159 at 24 h after the infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the lowest dose of 0.3 mg/kg, plasma tryptase was reduced by approximately 50%, including the subject with high baseline tryptase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At higher doses, tryptase levels were reduced below the lower limit of assay quantitation (LLoQ) (1 ng/ml) in all CDX‐0159 treated subjects for at least 3 weeks at 1 mg/kg, 6–14 weeks at 3 mg/kg and over 18 weeks at 9 mg/kg (Figure 4B and Figure S10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant change in tryptase was observed in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We observed dose‐proportional increases in SCF levels that mirrored the effects of CDX‐0159 on plasma tryptase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Together with the effect of the antibody on tryptase levels, these data provide additional evidence of systemic KIT saturation with CDX‐0159 at doses of 1 mg/kg and above.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum tryptase in healthy volunteers: single subcutaneous doses
Cold urticaria and symptomatic dermographism: skin mast cell depletion, tryptase, and SCF after one 3 mg/kg intravenous dose
Chronic inducible urticaria: kinetics of skin mast cell depletion and repopulation to Week 36
“Patients with two forms of CIndU (SD; n = 10 and ColdU; n = 10) received a single 3 mg/kg intravenous dose of barzolvolimab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As early as 1 week following drug administration, MC numbers rapidly decreased, reaching approximately 90% reduction after 8 weeks and with similar kinetics as reductions in serum tryptase and clinical symptoms (Figure S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MCs only recovered partially 36 weeks after dosing (31% for tryptase and 38% for CD117 from baseline), suggesting that MCs can repopulate skin, albeit very slowly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast to IHC data, MC transcripts completely recovered by Week 36 (Figure 2A) and the kinetics closely mirrored that of clinical symptoms and serum tryptase (Figure 2B–D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our data demonstrate that KIT‐dependent MC reduction is fully reversible and that mature and reactive MCs repopulate skin from MC progenitors within several weeks following their depletion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eosinophilic esophagitis: esophageal intraepithelial mast cell counts at Week 12, phase 2
Prurigo nodularis: serum tryptase with a 450 mg loading dose, phase 2
Prurigo nodularis: serum tryptase and plasma SCF after a single intravenous dose
Nonclinical toxicology in cynomolgus monkeys: bone marrow, red blood cell mass, and hair color
“To support human trials, a GLP‐compliant toxicology study was performed with CDX‐0159 in cynomolgus monkeys with dose levels of 1, 10, and 75 mg/kg administered every two weeks for 13 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CDX‐0159 was well tolerated with no significant changes in body weight, coagulation, clinical chemistry, ophthalmology, electrocardiography, respiratory, or neurological function during the treatment and recovery period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Observations attributed to CDX‐0159‐included minimal increases in the myeloid to erythroid ratio in bone marrow smears in the animals dosed at 10 and 75 mg/kg at the end of dosing (day 85), with evidence of recovery by day 141 despite continued drug exposure in the recovery period (Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, recoverable minimal/mild decreases in red blood cell mass parameters were observed (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hair color changes were noted in some high‐dose‐treated animals, consistent with inhibition of KIT activity in follicular melanocytes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Healthy volunteers, single intravenous doses: dose-proportional exposure and terminal half-life
“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CDX‐0159 serum levels were dose proportional and indicative of a PK profile with high exposure and long half‐life at higher doses, consistent with the expected effects of the YTE substitutions (Figure 4A and Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean terminal phase half‐life increased from 15 days at 0.3 mg/kg to 32 days at 9 mg/kg, which exceeds the average expected half‐life of 10–21 days for human IgG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results indicate a PK profile and volume of distribution consistent with those of a monoclonal antibody through this dosing range with evidence of target mediated clearance below approximately 5 μg/ml.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, the terminal half‐life of CDX‐0159 at a single 3 mg/kg dose was 23 days and was accompanied with tryptase suppression for >6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthy volunteers, single subcutaneous doses of 50 to 600 mg
Subcutaneous bioavailability, time to peak concentration, and half-life
No evidence found.
Nonclinical pharmacokinetics in cynomolgus macaques: effect of the YTE substitutions
“Consistent with previously published data with antibodies harboring YTE mutations, the pharmacokinetic properties of CDX‐0159 in cynomolgus macaques were indeed enhanced relative to CDX‐0158” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“terminal half‐life (22 ± 5.8 vs. 4.8 ± 3.5 days)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSU, multiple doses: dose-linear exposure, accumulation, and target saturation
“Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increased clearance and lower volumes of distribution were observed in patients who received lower doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Target saturation was observed with a durable clinical response and tryptase suppression with doses ≥ 1.5 mg/kg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic inducible urticaria, single 3 mg/kg intravenous dose: clearance, half-life, volume of distribution, and time to clearance
“Barzolvolimab pharmacokinetics in patients with CIndU (N = 20) following a single 3 mg/kg intravenous dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drug levels reach approximately 1 μg/mL by Week 12, as MC markers and clinical symptoms start to recover.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab is fully cleared after Week 18.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prurigo nodularis, single intravenous dose: terminal half-life and exposure by sex, weight, and antidrug antibody status
CSU: barzolvolimab concentrations during the 24-week follow-up period of the phase 2 trial
Immunogenicity: treatment-emergent antidrug antibodies and their effect on exposure and safety
“The impact of antidrug antibodies (ADA) on drug levels and safety was evaluated by comparing the area under the concentration–time curve (AUC) and the incidence of AEs for ADA‐positive versus ADA‐negative patients in each treatment group, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Antibarzolvolimab antibodies did not appear to impact the safety parameters in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity in the phase 2 and phase 3 CSU trials
No evidence found.
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information for Barzolvolimab
Not applicable.
Adverse events through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2
“Pooled EMBARQ-CSU1 and EMBARQ-CSU2” (opens the source at this quote in a new tab)
“Rate of SAEs similar across treatment groups” (opens the source at this quote in a new tab)
| Adverse event, n (%) | Placebo Q4W | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W |
|---|---|---|---|
| Participants (N) | “N=645” | “N=648” | “N=641” |
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |
Anaphylaxis adjudication through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2
“G3 anaphylaxis adjudicated as unlikely” (opens the source at this quote in a new tab)
“G2 angioedema/throat tightness/urticaria” (opens the source at this quote in a new tab)
“G3 anemia/neutropenia;” (opens the source at this quote in a new tab)
“G2 malaise/dyspnea/chest pain;” (opens the source at this quote in a new tab)
“G3 anaphylaxis after placebo administration” (opens the source at this quote in a new tab)
Anaphylaxis adjudication: phase 2 in cold urticaria and symptomatic dermographism
Anaphylactic reaction: prurigo nodularis phase 1b, 3.0 mg/kg intravenous dose
Neutropenia and infection rates: phase 3
“Placebo: 23.9%” (opens the source at this quote in a new tab)
“150 mg Q4W: 24.4%” (opens the source at this quote in a new tab)
“300 mg Q8W: 23.6%” (opens the source at this quote in a new tab)
“Placebo: 0.6%” (opens the source at this quote in a new tab)
“150 mg Q4W: 9.1%” (opens the source at this quote in a new tab)
“300 mg Q8W: 11.7%” (opens the source at this quote in a new tab)
Hematologic laboratory decreases: phase 1b intravenous dosing in chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections. Decreases in hematologic parameters were consistent with observations in healthy volunteers [10] and patients with chronic inducible urticaria [7] who received a single barzolvolimab dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hair color and skin pigmentation changes: phase 2 through Week 76
| Characteristic | Hair color changes | Skin hypopigmentation | Skin hyperpigmentation |
|---|---|---|---|
| Participants with the event | “n=49” | “n=36” | “n=6” |
| Grade 1, n (%) | “47 (96)” | “34 (94)” | “6 (100)” |
| Time to onset from start of barzolvolimab, days, mean (range) | “137 (7-397)” | “271 (107-424)” | “156 (11-283)” |
| Resolved at the time of data cutoff, n (%) | “40 (91)” | “19 (68)” | “4 (67)” |
| Time to resolution on treatment, days, median (95% CI) | “209 (119, 231)” | “110 (60, 120)” | “25 (7, NE)” |
| Time to resolution off treatment, days, median (95% CI) | “168 (138,189)” | “214 (196, 285)” | “NE” |
| Discontinued study treatment due to event, n (%) | “6 (3)” | “0 (0)” | “1 (<0.5)” |
Hair color changes: chronic inducible urticaria phase 1b
Taste changes: chronic inducible urticaria phase 1b
Taste changes: phase 1b in chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Taste changes, as noted in prior barzolvolimab studies, were reported by three patients (< 10%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infections: phase 1b in chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 40% of barzolvolimab‐treated patients and 20% of placebo‐treated patients experienced an infection AE. The infections that were reported by > 10% of barzolvolimab‐treated patients were COVID‐19 (14%), nasopharyngitis (11%), and UTI (11%), and were not correlated with neutrophil decreases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment discontinuations for adverse events: phase 2 through Week 52
| Disposition, n (%) | Barzolvolimab 75 mg Q4W, then 150 mg or 300 mg | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W | Placebo, then barzolvolimab 150 mg or 300 mg |
|---|---|---|---|---|
| Randomized | “n=53” | “n=52” | “n=52” | “n=51” |
| Discontinued treatment | “13 (25%)” | “13 (25%)” | “13 (25%)” | “8 (16%)” |
| Discontinued for an adverse event | “7 (13%)” | “4 (8%)” | “7 (13%)” | “2 (4%)” |
Reversibility off treatment: phase 2 follow-up to Week 76
Reversibility off treatment: chronic inducible urticaria phase 1b follow-up through Week 36
Phase 2 adverse events through Week 12
Phase 2 most common adverse events across doses
Phase 2 adverse events: placebo-controlled period to Week 16 and treatment period to Week 52
“Placebo Controlled Period (16 weeks)” (opens the source at this quote in a new tab)
“SAEs of worsening urticaria symptoms” (opens the source at this quote in a new tab)
“Adverse events were not dose dependent” (opens the source at this quote in a new tab)
| Participants, n (%) | Barzolvolimab, all doses, Weeks 0 to 16 | Placebo, Weeks 0 to 16 | Barzolvolimab, all doses, Weeks 0 to 52 | Placebo then barzolvolimab, 36 weeks of barzolvolimab |
|---|---|---|---|---|
| Participants (N) | “N= 156” | “N= 51” | “N= 156” | “N=48” |
| At least one adverse event | “103 (66)” | “20 (39)” | “139 (89)” | “32 (67)” |
| Treatment-related serious adverse events | “0” | “0” | “2 (1)” | “0” |
| Hair color changes | “22 (14)” | “0” | “40 (26)” | “8 (17)” |
| Neutropenia or neutrophil count decreased | “14 (9)” | “0” | “26 (17)” | “2 (4)” |
| Urticaria | “15 (10)” | “5 (10)” | “23 (15)” | “3 (6)” |
| Skin hypopigmentation | “2 (1)” | “0” | “21 (13)” | “9 (19)” |
| Nasopharyngitis | “6 (4)” | “3 (6)” | “15 (10)” | “4 (8)” |
Phase 1b adverse events at 24 weeks: intravenous dosing in chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TEAEs reported by system organ class and preferred term in ≥ 10% barzolvolimab‐treated patients at 24 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment-emergent adverse event, n (%) | All barzolvolimab | Pooled placebo |
|---|---|---|
| Participants (N) | “N = 35”View highlighted excerpt for this quote | “N = 10”View highlighted excerpt for this quote |
| Any treatment-emergent adverse event | “30 (86)”View highlighted excerpt for this quote | “6 (60)”View highlighted excerpt for this quote |
| Neutropenia | “5 (14)”View highlighted excerpt for this quote | “0 (0)”View highlighted excerpt for this quote |
| Leukopenia | “3 (9)”View highlighted excerpt for this quote | “0 (0)”View highlighted excerpt for this quote |
| Headache | “5 (14)”View highlighted excerpt for this quote | “2 (20)”View highlighted excerpt for this quote |
| Hair color changes | “9 (26)”View highlighted excerpt for this quote | “0 (0)”View highlighted excerpt for this quote |
“Overall, 30 barzolvolimab‐treated patients (86%) and 6 placebo‐treated patients (60%) experienced a TEAE. In the 1.5‐mg/kg group, two barzolvolimab‐treated patients (6%) experienced infusion‐related TEAEs. One patient (3%) in the 3.0‐mg/kg group experienced a TEAE that led to drug interruption. No patients experienced a dose‐limiting toxicity or any TEAE that led to treatment discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hair color change was the most common event, experienced by nine barzolvolimab‐treated patients (26%; Table 2); hair color changes occurred in different locations: scalp, beard, and body hair; and seven patients had this TEAE resolve by the end of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most AEs were mild or moderate in severity and resolved while on study. One SAE of Grade 4 salmonella gastroenteritis in a 59‐year‐old Black woman (1.5‐mg/kg group) was assessed by the investigator as unrelated to study treatment; she was treated with Levaquin, was discharged, and completed the study as planned.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity: antidrug antibodies in phase 1b chronic spontaneous urticaria
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Antibarzolvolimab antibodies did not appear to impact the safety parameters in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity: antidrug antibody status and exposure after a single intravenous dose in prurigo nodularis
Immunogenicity: risk factor text on antibodies against biologics
Chronic inducible urticaria phase 1b: single 3 mg/kg intravenous dose
Chronic inducible urticaria phase 2: Week 12 and Week 20 treatment periods
| Participants, n (%) | Barzolvolimab 150 mg Q4W | Barzolvolimab 300 mg Q8W | All barzolvolimab | Placebo |
|---|---|---|---|---|
| Participants (n) | “n=65” | “n=65” | “n=130” | “n=63” |
| Any adverse event | “40 (62%)” | “39 (60%)” | “79 (61%)” | “33 (52%)” |
| Treatment-related serious adverse events | “0” | “1 (2%)” | “1 (1%)” | “0” |
| Discontinued study treatment for adverse events | “1 (2%)” | “2 (3%)” | “3 (2%)” | “2 (3%)” |
| Hair color changes | “9 (14%)” | “8 (12%)” | “17 (13%)” | “0” |
| Neutropenia | “4 (6%)” | “9 (14%)” | “13 (10%)” | “0” |
Prurigo nodularis: adverse events after a single intravenous dose
Prurigo nodularis phase 2: 450 mg loading dose then 150 or 300 mg every 4 weeks
Eosinophilic esophagitis phase 2: 300 mg every 4 weeks through Week 44
Healthy volunteers: single intravenous doses of 0.3 to 9 mg/kg
“placebo‐controlled phase 1a healthy volunteer study of CDX‐0159” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1). A CDX‐0159 intravenous infusion was well tolerated at all doses. The most common adverse event (AE)s observed in thirteen out of twenty‐four subjects who received CDX‐0159 were mild, self‐limited infusion reactions that were consistently described as areas of local itching associated with erythema, and induration/hives, which started during the infusions (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mild decreases in hemoglobin levels generally within the normal range were observed, which rapidly stabilized despite the presence of high plasma drug levels (Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, all CDX‐0159 treatment groups showed variable, asymptomatic decreases relative to placebo on circulating neutrophils, which were also reflected in the total leukocyte count and did not further decline during the course of the study (Figure 3B,C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our healthy volunteer study, there were no reports of hair color changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment-emergent adverse event, n (%) | CDX-0159, all doses | Placebo |
|---|---|---|
| Participants (n) | “Total (n = 24)”View highlighted excerpt for this quote | “Placebo (n = 8)”View highlighted excerpt for this quote |
| Any event | “19 (79%)”View highlighted excerpt for this quote | “5 (63%)”View highlighted excerpt for this quote |
| Infusion-related reaction | “13 (54%)”View highlighted excerpt for this quote | “0 (0%)”View highlighted excerpt for this quote |
| White blood cell count decreased | “4 (17%)”View highlighted excerpt for this quote | “1 (13%)”View highlighted excerpt for this quote |
| Neutrophil count decreased | “4 (17%)”View highlighted excerpt for this quote | “1 (13%)”View highlighted excerpt for this quote |
| Sensation of foreign body in the throat | “3 (13%)”View highlighted excerpt for this quote | “0 (0%)”View highlighted excerpt for this quote |
Healthy volunteers: single ascending subcutaneous doses
Risk factor text on hypersensitivity, anaphylaxis, and injection-site reactions
Special populations
Age: eligibility from 18 to 75 years
“Eligible patients were aged 18–75 years and had CSU refractory to H1 antihistamine at approved or increased doses alone or in combination with H2 antihistamine and/or leukotriene receptor antagonists (LTRA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pediatric participants
No evidence found.
Pregnancy, nursing, and contraception for 150 days after treatment
Male fertility: spermatogenesis in the six-month non-human primate toxicology study
“In addition to its role in hematopoiesis, KIT signaling is important in other processes and has been described to have a role in hair pigmentation and spermatogenesis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effect of CDX‐0159 on fertility parameters will be studied in relevant preclinical models.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sex and body weight: effect on exposure in prurigo nodularis
Hepatic impairment: normal liver function tests required for enrollment
Renal impairment
No evidence found.
History of anaphylaxis and HIV, hepatitis B, or hepatitis C infection: exclusion criteria
Drug/Drug, drug/disease interactions
Effects of other drugs on Barzolvolimab
Clinical drug interaction studies
No evidence found.
Extrinsic participant-specific parameters and exposure: prurigo nodularis
Prior biologics, immunosuppressives, and oral doxepin: exclusion criteria
“Key exclusion criteria were receipt of prior biologic therapy (e.g., omalizumab, dupilumab, and ligelizumab) within the past 3 months or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half‐lives; treatment with doxepin (oral) within 4 weeks prior to study treatment; and any other skin disease associated with chronic itching that might confound study evaluations and results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effects of Barzolvolimab on other drugs
Clinical drug interaction studies
No evidence found.
Live vaccines avoided and inactivated vaccines allowed during the study
Dosing and administration
Dosage
Phase 3 regimens: 150 mg every 4 weeks after a 300 mg loading dose, or 300 mg every 8 weeks after a 450 mg loading dose
Dosing regimen named in the company summary of phase 3 data: every 4 weeks
Dose regimen proposed for licensure
No evidence found.
Phase 3b long-term extension retreatment regimen
| Group | Quoted arm description |
|---|---|
| Official title | “A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13” |
| Group 2 Barzolvolimab Retreatment Group | “Barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Group 1 Observation Group, worsening disease | “barzolvolimab will be administered once as a 300 mg subcutaneous injection followed by 150 mg every 4 weeks for up to 52 weeks.” |
Phase 2 regimens
| Arm | Quoted arm description |
|---|---|
| Barzolvolimab 75 mg then 150 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Barzolvolimab 75 mg then 300 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
| Barzolvolimab 150 mg | “barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
Phase 1b intravenous regimens in mg/kg
“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regimens with a 450 mg loading dose in cold urticaria, symptomatic dermographism, atopic dermatitis, and prurigo nodularis
Administration
Subcutaneous administration with potential self-administration at home
Intravenous infusion over 60 minutes in the phase 1b study
“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Access and distribution
Commercial-scale manufacturing at contract manufacturers and process performance qualification
Reliance on contract manufacturers for commercial supply, filling, packaging, storage, and shipping
Commercial organization and commercial planning
Distribution channel and patient support model
No evidence found.
Drug product process performance qualification timing, February 2026, superseded in November 2026
Co-prescribed/Concomitant therapies
Background second-generation H1 antihistamine at a stable regimen in the phase 3 trials
Live vaccines excluded within 30 days before screening in the phase 3 trials; inactivated vaccines allowed
Phase 3b long-term extension observation group: standard of care with at least second-generation H1 antihistamines
Phase 2 background H1 antihistamine and live vaccine exclusion within 2 months
Phase 1b add-on to H1 antihistamine alone or with H2 antihistamine or leukotriene receptor antagonist, with rescue antihistamines
“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion). Rescue treatments were allowed up to maximum allowable doses: diphenhydramine 100 mg 4× daily (QID), hydroxyzine 50 mg QID, or H2 antihistamine 4× the recommended dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was limited by the small sample size and variation in drugs used for background urticaria treatment; however, patients had to be on a stable regimen prior to barzolvolimab administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of Barzolvolimab on quality measures
AAAAI and ACAAI urticaria measures: laboratory test overuse and antihistamine updosing underuse
Recommendation against routine extensive testing in chronic urticaria
Physician adherence to CSU guidelines in a multinational online survey of dermatologists and allergists, Novartis-funded
“This is a multinational cross-sectional online survey involving patients with CSU and CSU-treating physicians from seven countries (USA, Canada, UK, Germany, France, Italy, and Japan).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 862 physicians (517 dermatologists; 345 allergists) participated in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Globally, 56% of physicians adhered to guidelines, 19% followed therapeutic protocols, and approximately 30% did not adhere to any guideline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study and the journal’s Rapid Service Fees were funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physician awareness of and adherence to CSU guidelines, Genentech-funded study
“Finally, some physicians are not aware of, or do not adhere to, international guidelines available for the treatment of CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Genentech, Inc, a member of the Roche Group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Product-specific effect on quality measures
No evidence found.
Product comparison
Absence of head-to-head trials: company statement on cross-study comparisons
Barzolvolimab: phase 3 dosing regimens and planned BLA submission
Barzolvolimab: subcutaneous pre-filled syringe and potential self-administration at home
Barzolvolimab: Week 12 UAS7 change and UAS7=0 in EMBARQ-CSU1 and EMBARQ-CSU2
| Arm | EMBARQ-CSU1 LS mean change (SE) in UAS7 at Week 12 | EMBARQ-CSU2 LS mean change (SE) in UAS7 at Week 12 | EMBARQ-CSU1 UAS7=0 at Week 12 | EMBARQ-CSU2 UAS7=0 at Week 12 |
|---|---|---|---|---|
| Placebo | “-10.7 (0.65)” | “-11.4 (0.64)” | “9.3%” | “12.6%” |
| Barzolvolimab 150 mg every 4 weeks | “-20.2 (0.64)” | “-20.2 (0.63)” | “42.4%” | “45.7%” |
| Barzolvolimab 300 mg every 8 weeks | “-20.5 (0.65)” | “-19.7 (0.64)” | “42.1%” | “44.0%” |
Omalizumab: CSU indication, subcutaneous dosing every 4 weeks, and administration setting
Omalizumab: anaphylaxis boxed warning
Omalizumab: UAS7=0 at Week 12 in CSU Trial 1
Dupilumab: CSU indication and subcutaneous dosing every 2 weeks in adults
Dupilumab: CUPID Study A and Study C results at Week 24, and Study B
| Outcome at Week 24 | CUPID Study A dupilumab (N=68) | CUPID Study A placebo (N=68) | CUPID Study C dupilumab (N=73) | CUPID Study C placebo (N=75) |
|---|---|---|---|---|
| LS mean change (SE) in UAS7 | “-20.99 (1.77)” | “-11.95 (1.81)” | “-15.61 (2.62)” | “-11.27 (2.61)” |
| UAS7 ≤6, n (%) | “32 (47.1)” | “16 (23.5)” | “29 (39.7)” | “17 (22.7)” |
| UAS7 = 0, n (%) | “22 (32.4)” | “9 (13.2)” | “22 (30.1)” | “13 (17.3)” |
Remibrutinib: CSU indication in adults and oral dosing twice daily
Remibrutinib: UAS7 change, UAS7 ≤6, and UAS7 = 0 at Week 12 in REMIX-1 and REMIX-2
| Outcome at Week 12 | REMIX-1 remibrutinib (N = 309) | REMIX-1 placebo (N = 153) | REMIX-2 remibrutinib (N = 297) | REMIX-2 placebo (N = 153) |
|---|---|---|---|---|
| LS mean (SE) change in UAS7 | “-20.02 (0.72)” | “-13.79 (0.98)” | “-19.41 (0.70)” | “-11.73 (0.95)” |
| UAS7 ≤6, n (%) | “154 (49.8)” | “38 (24.8)” | “139 (46.8)” | “30 (19.6)” |
| UAS7 = 0, n (%) | “96 (31.1)” | “16 (10.5)” | “83 (27.9)” | “10 (6.5)” |
Draft joint task force guideline: direct and retail prices of omalizumab, dupilumab, and remibrutinib as of December 2025
| Medication | Example packages | Direct price | Retail price |
|---|---|---|---|
| Omalizumab | “1 syringe/pen per box” | “$1475 per month” | “$1,525.61 per 150mg” |
| Dupilumab | “Carton” | “$4,193.03 per carton” | “$3100.84-5132.09 per carton” |
| Remibrutinib | “60 tablets” | “$4,424.01 per bottle” | “$4,521 per bottle” |
International guideline: dupilumab effect relative to omalizumab, oral remibrutinib, and cost restrictions
“Results of Phase 3 studies show the efficacy of dupilumab as add‐on treatment, which is however, likely to be less pronounced than those observed with omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In September 2025 remibrutinib was approved by the FDA as an oral treatment for adult patients with CSU who remain symptomatic despite H1‐antihistamine treatment and does not require injections or lab monitoring” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis for the joint task force guideline: omalizumab and remibrutinib among the most effective
Network meta-analysis of biologic and targeted synthetic treatments for antihistamine-refractory CSU
“Most biological and synthetic target‐specific drugs for antihistamine‐refractory chronic spontaneous urticaria (CSU) have not been compared head‐to‐head.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“23 randomized clinical trials with 6933 participants that compared 26 different interventions or dosages and placebos were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Omalizumab 300 mg [MD −10.07, 95% CI (−11.35; −8.82)] continues to demonstrate superior efficacy compared with placebo. Remibrutinib, at doses of 35 mg once daily [MD −7.80, 95% CI (−12.76; −2.51)], 25 mg twice daily [MD −7.69, 95% CI (−9.85; −5.76)], and 10 mg twice daily [MD −7.61, 95% CI (−12.59; −2.47)], had the best overall performance for efficacy and safety. Dupilumab, fenebrutinib, and rilzabrutinib also showed greater efficacy than placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant differences were found among all treatment comparisons for AEs and SAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of omalizumab, dupilumab, and remibrutinib at Weeks 12 and 24
“Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), Dermatology Life Quality Index (DLQI; DLQI 0/1), disease control (UAS7 ≤ 6), and symptom remission (UAS7 = 0) were assessed at weeks 12/24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints. Remibrutinib showed the greatest DLQI improvement and second-highest UAS7 reduction and odds of symptom remission. Dupilumab provided sustained itch relief but delayed efficacy. Lower omalizumab doses lacked durability at 24 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time to minimal clinically important difference in UAS7 across approved and investigational therapies
“This study aims to provide indirect evidence on the relative time to meaningful clinical response across approved and investigational therapies using a Bayesian network meta-analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome was the mean time in weeks to minimal clinically important difference (MCID), defined as a UAS7 reduction of 10 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only omalizumab 300 mg every 4 weeks, dupilumab 300 mg every 2 weeks, and ligelizumab 72 mg and 120 mg every 4 weeks achieved statistically significant reductions compared with placebo. All treatments had wide credible intervals reflecting limited direct comparisons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Matching-adjusted indirect comparison of omalizumab versus dupilumab at Week 12
“Pooled patient-level data from the omalizumab ASTERIA I/II trials ( NCT01287117 /01292473) were compared with published aggregate data from the dupilumab LIBERTY-CSU CUPID Study A trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Improvements in both disease activity and itch severity were statistically significantly greater for omalizumab versus dupilumab (least squares mean [95% confidence interval] difference: UAS7, −7.6 [−13.0, −2.2], P = .006; ISS7, −3.0 [−5.8, −0.3], P = .031).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Change from baseline in UAS7 at week 12 for omalizumab versus placebo was −12.6 (−15.7, −9.5) and for dupilumab versus placebo was −5.0 (−9.3, −0.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place of product in therapy
Disease description
Definition and etiology
Definition of urticaria, wheals, and angioedema in the international guideline
“Urticaria is a condition characterized by the development of wheals (hives), angioedema, or both.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A wheal has three typical features: a sharply circumscribed superficial central swelling of variable size and shape, almost invariably surrounded by reflex erythema, an itching or sometimes burning sensation, a fleeting nature, with the skin returning to its normal appearance, usually within 30 min to 24 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Angioedema is characterized by: a sudden, pronounced erythematous or skin colored deep swelling in the lower dermis and subcutis or mucous membranes, tingling, burning, tightness, and sometimes pain rather than itch, a resolution slower than that of wheals (can take up to 72 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Classification by duration and by eliciting factors: acute versus chronic at 6 weeks, spontaneous versus inducible
“Urticaria is classified based on two main criteria: (i) its duration, as acute or chronic, and (ii) the role of definite triggers, categorized as inducible or spontaneous.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Acute urticaria is defined as the occurrence of wheals, angioedema or both for 6 weeks or less.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic urticaria (CU) is defined as the occurrence of wheals, angioedema, or both for more than 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When the clinical course has no definite physical eliciting factor involved and shows a spontaneous course, it is described as chronic spontaneous urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inducible urticaria is characterized by the presence of definite and subtype‐specific triggers leading to the development of wheals, angioedema, or both” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that urticaria is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that urticaria is classified as spontaneous (no definite eliciting factor involved) or inducible (specific definite factor involved)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic spontaneous urticaria with known and unknown causes in the guideline classification
“Spontaneous appearance of wheals, angioedema or both for > 6 weeks due to known” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CSU comes as CSU with known cause and CSU with unknown cause.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, Type I autoimmunity (autoallergy) and type IIb autoimmunity, with mast cell‐activating autoantibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CU patients can concomitantly show more than one form of CU including more than one form of CIndU and they often do.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic spontaneous urticaria as a share of chronic urticaria in the draft AAAAI/ACAAI JTF guideline
Former name: chronic idiopathic urticaria
“CU can be classified as chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria and marked by the spontaneous appearance of hives and angioedema due to unknown causes) and chronic inducible urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: definitions in the Joint Task Force practice parameter
Etiology: autoimmunity as the identified cause of chronic spontaneous urticaria
“Although CSU pathogenesis is not yet fully understood, it is well established that its signs and symptoms are due to the activation of skin mast cells and the subsequent release and effects of their mediators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In more than 50% of CSU patients, the pathophysiology is driven by two main autoimmune mechanisms: Type I (autoallergy) involving IgE autoantibodies against autoallergens, and type IIb involving IgG autoantibodies; a subpopulation of patients with CSU has both types” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is also important to explain to the patient that CU is predominantly an autoimmune condition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, autoimmunity, either of Type 1 viz. IgE antibodies to local autoallergens, or Type 2b, viz. IgG autoantibodies to IgE or its receptor, are considered to be the most frequent causes of CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: infections, malignancy, thyroid disease, food, and drugs
“Acute urticaria frequently follows upper airways infections” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In rare instances, chronic (silent) infections may contribute to CSU, and very rarely, an underlying malignancy has been reported” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other potential underlying causes include active thyroid disease, infections, cancer, inflammatory processes, food, and drugs, though these factors can be both causative as well as aggravating” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intensive and costly general screening programs for causes of urticaria are not advised.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IgE‐mediated food allergy is extremely rarely the underlying cause of CSU” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: type 1 allergen sensitization not causal in a Berlin population survey
“A questionnaire survey was sent to a representative cross-sectional sample of 13,300 inhabitants of Berlin, Germany, of whom 4093 responded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Prick tests found sensitization of ≥ 1 for type 1 allergens in 39.1% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These were related to comorbidities such as allergic rhinitis or oral allergy syndrome, but were never the underlying cause of CU, as proven by double-blind, placebo-controlled provocation tests.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aggravating factors: NSAIDs, stress, and infections
“Some patients suffering from CSU experience trigger‐induced augmentation of wheals, angioedema, or both.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among others, these triggers include stress and infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Non‐IgE‐mediated reactions to drugs can also augment the activity of preexisting CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NSAIDs are the most common drugs to do so in up to one‐fourth of patients, except for paracetamol (acetaminophen) and/or COX‐2 inhibitors which are considered to be safer options in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors in an Italian general practitioner database: obesity, anxiety disorders, malignancy, immunosuppressants, and smoking
“The risk of CSU was statistically significantly higher in the presence of the following variables: obesity; anxiety, dissociative and somatoform disorders; malignancies; use of immunosuppressive drugs; and chronic use of systemic corticosteroids.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“History of autoimmune thyroiditis showed a trend towards an increased risk of CSU, though it was not statistically significant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Smoking was associated with a significantly reduced risk of CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Children: causes and characteristics similar to adults
“Recent reports indicate that, in children, the prevalence of CIndUs and CSU, as well as disease characteristics, underlying causes of CSU, and response to treatment, are very similar to those observed in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Chronic spontaneous urticaria
United States: incidence of diagnosed CSU in three US databases, 2012 to 2018, Novartis-funded
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data identification period for Optum EHR and Optum CDM was from January 1, 2012 to December 31, 2018, and for MarketScan it was January 1, 2012 to December 31, 2017.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The target population was identified using three anonymized databases: Optum Electronic Health Record (EHR), Optum Clinformatics Data Mart (CDM), and Truven Health MarketScan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incident cohorts included newly identified patients with the first urticaria or angioedema code within the year of interest and no codes 12 months prior to that year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Optum EHR, the age- and sex-standardized incidence rate (95% CI) among adults and pediatric patients during the identification period was 0.039 (0.039–0.039) and 0.066 (0.065–0.067) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age-standardized incidence rate (95% CI) of CSU among the adult and pediatric populations during the identification period in Optum CDM was 0.094 (0.093–0.095) and 0.109 (0.107–0.111) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In MarketScan, the age-standardized incidence rate (95% CI) of CSU among adults and pediatric patients during the identification period was 0.102 (0.097–0.107) and 0.097 (0.096–0.098) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study also reports for the first time, to the best of our knowledge, standard incidence rate of diagnosed CSU in the USA, with period estimates among adults ranging from 0.039 to 0.102 per 100 person-years in the three databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: combined adult and pediatric incidence of diagnosed CSU and annual trend, Novartis-funded study
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sex-standardized combined (adult and pediatric) incidence rate and prevalence (95% CI) were 0.096 (0.096–0.097) per 100 person-years and 0.283% (0.281–0.284), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sex-standardized combined (adult and pediatric) incidence rate and prevalence (95% CI) were 0.088 (0.087–0.088) per 100 person-years and 0.244% (0.243–0.245), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual incidence rate ranged from 0.031 in 2012 to 0.069 per 100 person-years in 2018 across the three databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparatively, the incidence and prevalence were higher among pediatric patients than adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: average annual incidence of diagnosed CSU of 0.08% in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors
“Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Age- and gender-adjusted prevalence/incidence rates were calculated for January 2017 to December 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average annual incidence rate was 0.08%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“US Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, New Jersey” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: chronic urticaria incidence estimate in the Joint Task Force practice parameter
Italy: incidence of CSU in a general practitioner database, 2002 to 2013
“The study population was formed by patients aged ≥ 15 years, registered with a total of 700 general practitioners, homogeneously distributed across Italy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual prevalence and incidence rates of CSU over a 12-year period (2002-2013) were estimated, along with demographic and clinical determinants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence was 0·10-1·50 per 1000 person-years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For both prevalence and incidence rates, female patients outnumbered male.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Italy: incidence of newly diagnosed CSU in primary care, 2002 to 2022
“A cohort of patients aged 15 years and older with newly diagnosed CSU was identified from Italian primary care data from January 1, 2002, to September 30, 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence was 2.07-1.93 per 1000 person-years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A cohort of 7,018 patients with CSU was identified during the study period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global: urticaria incidence in the Global Burden of Disease 2021 study
“We utilized data from the Global Burden of Disease (GBD) Results (2021) to obtain prevalence, incidence, and disability-adjusted life years (DALYs) for urticaria from 1990 to 2021, categorized by age, gender, and region.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regarding incidence, the total number of urticaria cases rose from 84,870,288 (74,471,430 − 96,206,256) in 1990 to 117,014,587 (104,106,688 − 131,017,656) in 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence rate declined from 1591.23 (1396.26-1803.77) per 100,000 population in 1990 to 1482.82 (1319.25-1660.27) in 2021, with an EAPC value of 0.01 (0.01–0.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As shown in Fig. 1 , across all age groups, females generally have higher incidence and DALYs compared to males.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Projections indicate a continued rise through 2046.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Region | Age-standardized incidence rate, 1990 | Age-standardized incidence rate, 2021 |
|---|---|---|
| High-income North America | “1569.62 (1461.56-1669.2)”View highlighted excerpt for this quote | “1602.35 (1507.35-1697.23)”View highlighted excerpt for this quote |
| Global | “1529.24 (1355.9-1720.36)”View highlighted excerpt for this quote | “1533.71 (1358.35-1726.07)”View highlighted excerpt for this quote |
Prevalence of Chronic spontaneous urticaria
United States: diagnosed CSU period prevalence in three US databases, 2012 to 2018, Novartis-funded
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study population consisted of adult (aged ≥ 18 years) and pediatric (aged < 18 years) patients with diagnosed CSU based on ≥ 2 relevant International Classification of Diseases version 9 and/or 10 (ICD-9 and/or ICD-10) codes recorded ≥ 6 weeks apart.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age- and sex-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum EHR during the identification period (2012–2018) was 0.039 and 0.066 per 100 person-years, respectively, while the prevalence was 0.120% and 0.193%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum CDM (2012–2018) was 0.094 and 0.109 per 100 person-years, respectively, while the prevalence was 0.277% and 0.304%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in MarketScan (2012–2017) was 0.102 and 0.097 per 100 person-years, respectively, while the prevalence was 0.256% and 0.264%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our study reports the standardized period prevalence of diagnosed CSU among adults from 0.120% to 0.277% across three databases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: annual prevalence trend of diagnosed CSU, 2012 to 2018, Novartis-funded study
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual standardized prevalence of diagnosed CSU among adults across three databases increased from 0.052% in 2012 to 0.191% in 2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The standardized period prevalence of diagnosed CSU among pediatric patients ranged from 0.193% to 0.304% across the three databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The findings of this study highlight a general increasing trend in the incidence and prevalence of diagnosed CSU over time among the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“most of the patients (≥ 80%) were diagnosed with unspecified urticaria, followed by idiopathic urticaria and other urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: cumulative prevalence of diagnosed CSU of 0.57% in adults in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors
“Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Age- and gender-adjusted prevalence/incidence rates were calculated for January 2017 to December 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 200,298 patients were followed-up for a median of 2.3 years after diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated cumulative prevalence of diagnosed CSU was 0.57% (women: 0.80%; men: 0.32%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic spontaneous urticaria (CSU) is an unpredictable inflammatory skin condition with substantial clinical burden that affects 0.23% to 0.78% of the US population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“US Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, New Jersey” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: 12-month prevalence of self-reported physician-diagnosed CSU of 0.78% in adults, 2019 National Health and Wellness Survey, Novartis-funded
“This cross-sectional study used data from the 2019 NHWS, a nationally representative sample of the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adults who self-reported receiving a diagnosis of CSU from a healthcare provider in the past 12 months were included in the analysis for all outcomes and for the calculation of the weighted 12-month prevalence of diagnosed CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The weighted prevalence (95% confidence interval) of diagnosed CSU was 0.78% (0.78%–0.78%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: chronic urticaria prevalence of 0.23% in adults, cross-sectional electronic health records analysis
“To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A cross-sectional analysis with electronic health records data for a demographically heterogeneous population-based sample of >55 million patients across all 4 census regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall CU prevalence was 0.23%, or 230 CU cases/100,000 adults.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There are >500,000 people estimated to have CU in the United States, most of whom are women or adults ≥40 years of age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Use of administrative data has the potential to underestimate burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
North America: chronic urticaria point prevalence of 0.1% in a global meta-analysis
“The objective of this study was to systematically evaluate and summarize the prevalence of chronic urticaria by evaluating population-based studies worldwide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We performed a systematic search in PUBMED and EMBASE for population-based studies of cross-sectional or cohort design and studies based on health insurance/system databases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eighteen studies were included in the systematic evaluation and 11 in the meta-analysis including data from over 86 000 000 participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Asian studies combined showed a higher point prevalence of chronic urticaria (1.4%, 95%-CI 0.5-2.9) than those from Europe (0.5%, 0.2-1.0) and Northern American (0.1%, 0.1-0.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The four studies that examined time trends indicated an increasing prevalence of chronic urticaria over time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: chronic urticaria prevalence range and female to male ratio in the Joint Task Force practice parameter
United States: chronic urticaria prevalence in adults by sex, age, and race
“To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The adjusted prevalence in women was 310 (95% confidence interval [CI] 307-312) cases/100,000 adults, more than twice that of men (146 [95% CI 143-148] cases/100,000 adults, P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CU prevalence was highest among patients aged 40-49 years (256 [95% CI 252-261] cases/100,000 adults) and 50-59 years (246 [95% CI 242-251] cases/100,000 adults) compared with all other age groups (P < .0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted prevalences for black (292 [95% CI 285-298] cases/100,000 adults) and other (331 [95% CI 323-338] cases/100,000 adults) patients were higher than that for white patients (262 [95% CI 260-264] cases/100,000 adults; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States by age: higher diagnosed CSU prevalence in pediatric than adult populations, Novartis-funded study
| Database and period | Adults (aged 18 years or older), prevalence (95% CI) | Pediatric patients (aged under 18 years), prevalence (95% CI) |
|---|---|---|
| Optum EHR, 2012 to 2018 | “0.120% (0.119–0.120)”View highlighted excerpt for this quote | “0.193% (0.191–0.195)”View highlighted excerpt for this quote |
| Optum CDM, 2012 to 2018 | “0.277% (0.275–0.279)”View highlighted excerpt for this quote | “0.304% (0.300–0.308)”View highlighted excerpt for this quote |
| MarketScan, 2012 to 2017 | “0.256% (0.248–0.265)”View highlighted excerpt for this quote | “0.264% (0.261–0.266)”View highlighted excerpt for this quote |
“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of CSU in the present study was higher among pediatric patients than among adults across all databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: age at diagnosis and sex of adults with self-reported diagnosed CSU, Novartis-funded survey
“This cross-sectional study used data from the 2019 NHWS, a nationally representative sample of the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (standard deviation [SD]) age at diagnosis was 37.0 (17.1) years, and 51.7% of respondents were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Female predominance from age 31 years in the international CURE registry
“We analysed Chronic Urticaria Registry (CURE) data, an international real‐world registry for patients with chronic urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statistically significant female predominance started at age 31 (<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CSU demonstrates a pronounced sex disparity, with females being disproportionately affected—evidenced by at least twofold higher incidences in females compared with males.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Children: no sex difference in chronic urticaria prevalence under age 15 years
Children in five European countries: one-year diagnosed CSU prevalence of 0.75% from a physician survey
“A physician-based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across 5 European countries, the one-year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94-1.86) and 0.75% (95% CI, 0.44-1.08), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Germany: lifetime and 12-month prevalence of chronic urticaria in a representative Berlin population survey
“A questionnaire survey was sent to a representative cross-sectional sample of 13,300 inhabitants of Berlin, Germany, of whom 4093 responded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lifetime prevalence rate of urticaria was 8.8% (95% CI 7.9-9.7%) for all types of urticaria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lifetime prevalence for CU was 1.8% (95% CI 1.4-2.3%), and prevalence for the 12 months before assessment was 0.8% (95% CI 0.6-1.1%), and 70.3% were female.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Italy: annual prevalence of CSU in a general practitioner database, 2002 to 2013
“The study population was formed by patients aged ≥ 15 years, registered with a total of 700 general practitioners, homogeneously distributed across Italy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual prevalence of CSU ranged from 0·02% in 2002 to 0·38% in 2013.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For both prevalence and incidence rates, female patients outnumbered male.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Italy: annual prevalence of CSU in primary care, 2002 to 2022
“A cohort of patients aged 15 years and older with newly diagnosed CSU was identified from Italian primary care data from January 1, 2002, to September 30, 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Annual CSU prevalence ranged from 0.41% in 2002 to 0.35% in 2022.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global: urticaria prevalence and female share in the Global Burden of Disease 2021 study
“Globally, the total number of urticaria cases increased from 47,949,600 (42,267,752 − 54,859,773) in 1990 to 66,483,473 (59,240,738 − 74,912,351) in 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meanwhile, the prevalence rate decreased from 899.01 (792.48-1028.56) per 100,000 population in 1990 to 842.49 (750.70-949.30) per 100,000 population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 2021, females accounted for 58.94% of the total urticaria cases, with a female/male ratio of 1.44.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global: lifetime prevalence of urticaria
“The lifetime prevalence of acute urticaria is estimated to be approximately 20%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Urticaria is a frequent disease affecting up to 20% of the world population at some point during their lifetime, with over half of those patients reporting angioedema, and the global prevalence continues to increase” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Chronic course and recurrence after remission: 2026 international guideline
“Chronic urticaria (CU) is defined as the occurrence of wheals, angioedema, or both for more than 6 weeks. CU can come with daily, or almost daily, signs and symptoms, or an intermittent/recurrent course.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CSU episodes may recur after months or years of full remission” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since the severity of urticaria may fluctuate, and spontaneous remission may occur at any time, it is also recommended to re‐evaluate the necessity for continued or alternative drug treatment every three to 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Predictors of prolonged disease duration: 2026 international guideline
“In CSU, disease duration, disease activity, and response to treatment are linked to clinical characteristics and laboratory markers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, the presence of concomitant CIndU, high disease activity, elevated CRP and/or the presence of angioedema are indicative for a prolonged duration of CSU and suboptimal response to antihistamine treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission rates at years 1, 5, and 20: targeted literature review
“The objectives of this targeted literature review were to identify evidence on the clinical course of CSU, including remission rates, and to estimate cumulative remission rates for different time points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ten publications were included in this review. The proportion of patients achieving remission within year 1 ranged from 21 to 47%, while reported remission rate estimates at year 5 were 34% and 45%. Based on calculated 4-weekly remission rates, cumulative remission estimates ranged from 9 to 38% at year 1, from 29 to 71% at year 5 and from 52 to 93% at year 20. Cumulative weighted average estimates for the proportion of patients remitting at years 1, 5 and 20 were 17%, 45% and 73%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, data sources differed in terms of definitions of disease severity and remission, as well as in conclusions on influencing factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average disease duration in CSU has been estimated to be 5 years, although it may persist longer in severe cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission and relapse clusters in chronic urticaria: electronic health record cohort of 112,443 adults
“Adults with a CU diagnosis and confirmation CU diagnosis/CU-related treatment at least 6 weeks later were identified in the Optum® de-identified Electronic Health Record dataset (2007–2018). Active CU was a period during which a patient was not in clinical remission. Clinical remission was defined as at least 12 months without CU diagnosis and/or treatment. Relapse was defined as having a CU diagnosis and/or treatment following clinical remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 112,443 patients were grouped into four clusters. Cluster 1 ( N = 36,690 [32.6%]) had the shortest median time to clinical remission (4.1 months) and lowest relapse rate (38.0%). Cluster 2 ( N = 29,834 [26.5%]) reached clinical remission later (10.0 months), with a higher relapse rate (52.3%). Clusters 3 ( N = 24,093 [21.4%]) and 4 ( N = 21,826 [19.4%]) had the longest median times to clinical remission (33.8 and 44.6 months) and highest relapse rates (75%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission of chronic urticaria: national sample cohort with 10-year follow-up
“Patients with new-onset urticaria were identified from the National Health Insurance Service-National Sample Cohort data.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 10-year cumulative incidence rate of urticaria for the general population was 4.9% and that of chronic urticaria among patients with new-onset urticaria was 7.8%. Remission rates of chronic urticaria were 52.6% at 1 year and 88.9% at 5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Remission was achieved in the majority of patients with chronic urticaria regardless of demographic characteristics or accompanying thyroid disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remission of chronic urticaria: 329 Korean participants in three university hospitals
“Total 329 Korean patients with CU, who had follow-ups more than 6 months after diagnosis during a 7-year period in the department of dermatology in three university hospitals were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion recovered in 1, 3, and 5 years after the onset of CU was 10.8%, 18.8%, and 32.9%, respectively. The mean duration of CU was 6.3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission in children with chronic urticaria: 77 children followed for at least 48 months
“We evaluated 77 children diagnosed with CU, who were monitored for at least 48 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remission was defined as having no symptoms without treatment for more than 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The remission rates at 6 months, 1 year, 2 years, 3 years, and 4 years after symptom onset were 22.1%, 40.3%, 52.0%, 63.7%, and 70.2%, respectively, for children with CU. For children with CSU, these values were 23.4%, 43.7%, 56.2%, 68.7%, and 75.0%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission in children with chronic urticaria: 92 children aged 4 to 15 years
“Children 4 to 15 years of age with CU were investigated with a complete blood cell count, erythrocyte sedimentation rate, antinuclear antibody titer, complement CH50 level, thyroid studies, autologous serum skin test, skin-prick tests, food challenges, and stool examination for parasites.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In all, 92 children (53.3% female) with CU were recruited and followed up for a median duration of 4.3 years (range 2.5-5.8 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Remission rates at 1, 3, and 5 years after the onset of CU symptoms were 18.5%, 54%, and 67.7%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disease duration: physician-diagnosed CSU in a 2019 United States survey
“To estimate the burden, clinical profile, and prevalence of diagnosed CSU in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) disease duration was 11.0 (12.6) years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
All-cause mortality: propensity score-matched electronic health record cohort, TriNetX
All-cause mortality by treatment exposure, including oral corticosteroids
Mortality analysis limitations stated by the authors
Pathophysiology
Mast cell activation as the central mechanism
“Urticaria is predominantly a mast cell‐driven disease but the triggers that activate mast cells are heterogeneous, diverse, and vary from patient to patient” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the result of mast cell activation is the release of mediators such as histamine and platelet activation factor (PAF), among others, which are responsible for sensory nerve stimuli (pruritus), vasodilatation (erythema), and inflammatory cells chemoattraction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Histologically, wheals are characterized by degranulated mast cells, with edema of the upper‐ and mid‐dermis, with dilatation and augmented permeability of the postcapillary venules as well as lymphatic vessels of the upper dermis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In angioedema, similar changes occur primarily in the lower dermis and the subcutis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Skin mast cells as the primary effector cell, with increased numbers in lesional and non-lesional skin
“This review presents evidence that the skin mast cell, in particular the MCTC subtype, is the primary effector cell in urticaria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Increased numbers of mast cells are found in both lesional and non-lesional skin in CSU and inducible urticaria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Histamine, PGD2 and tryptase are found in the venous blood draining wheal formation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The last 2 are specific for mast cells rather than basophils.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other cells, receptors, and pathways: T cells, B cells, eosinophils, basophils, MRGPRX2, complement, and coagulation
“Other than the histamine receptor, there are other receptors on mast cells that are also involved, such as the Mas‐related G‐protein coupled receptor member X2 (MRGPRX2)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition to mast cells, several other cells and mediators can contribute to the pathology of CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These include T cells (i.e., interaction via OX40/OX40L, T cell cytokines), B cells (autoantibody production), eosinophils (i.e., release of MRGPRX2 agonists), neutrophils or basophils, macrophages, sensory nerves (i.e., release of neuropeptides), and others” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The non‐lesional skin of CSU patients has been shown to exhibit an upregulation of adhesion molecules, infiltrating eosinophils, altered cytokine expression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Also, a significant number of CSU patients show signs of type 2 inflammation‐driven comorbidities” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Autoimmune endotypes: type I (autoallergic) and type IIb autoimmune CSU
“In more than 50% of CSU patients, the pathophysiology is driven by two main autoimmune mechanisms: Type I (autoallergy) involving IgE autoantibodies against autoallergens, and type IIb involving IgG autoantibodies; a subpopulation of patients with CSU has both types” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type I autoallergic CSU: IgE autoantibodies to thyroid peroxidase and other autoantigens
Type IIb autoimmune CSU: 8% meeting all three criteria in a multinational study of 182 participants
“This was a multinational, multicenter study of 182 CSU patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 182 patients, 107 (59%) were ASST+, 46 (25%) were BASO+, and 105 (58%) were IgG anti-FcεRI+/IgE+.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen patients (8%) fulfilled all three criteria of aiCSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“aiCSU patients appeared more severe (UAS7 21 vs 9 P < 0.016) but showed no other clinical or demographic differences from non-aiCSU patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“aiCSU patients also had markedly lower total IgE levels (P < 0.0001) and higher IgG anti-TPO levels (P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of biomarkers, positive BAT and BHRA tests were 69% and 88% predictive of aiCSU, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Type IIb autoimmune CSU: prevalence by number of positive markers
Biomarkers of type IIb autoimmune CSU: low total IgE, elevated IgG-anti-TPO, basopenia, eosinopenia, and basophil tests
“We analyzed records of patients with CSU from 2 independent cohorts (n = 1120) for demographic, clinical, and laboratory parameters and treatment responses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cutoff values were greater than or equal to 34 kU/L (high aTPO) and less than 40 IU/mL (low total IgE).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One of 10 patients with CSU had both high aTPO and low IgE (aTPO↑IgE↓, 11%, n = 123).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Almost half the patients with aTPO↑IgE↓ (44%, 19 of 43) had a positive BAT result, the best single marker for aiCSU, versus 12% (43 of 344) of patients without aTPO↑IgE↓ (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with aTPO↑IgE↓ showed low response rates to antihistamine treatment as compared with patients without aTPO↑IgE↓ (30% vs 47%; P = .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 1,058 records found in the search, 94 studies were reviewed by experts in urticaria and 42 were included in the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In CSU patients, BAT/BHRA+ showed a strong level of evidence for an association with high disease activity and low levels of total IgE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A weak level of evidence was shown for the association of BAT/BHRA+ and the presence of angioedema, and basopenia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biomarkers in clinical practice: total IgE and IgG-anti-TPO, with limited diagnostic accuracy
“In patients under specialist care, additional tests, such as total IgE and IgG‐anti‐TPO may be performed, as they indicate the likelihood of response to omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the established statistical association, the diagnostic performance and predictive accuracy of these tests remains limited” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, although a clinical association between these laboratory markers and urticaria endotypes has been demonstrated, their clinical usefulness remains limited because there are no studies evaluating their diagnostic accuracy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, cutoff points can be suggested but cannot be recommended for definitive endotype classification” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Validated biomarkers assays are currently under development and are needed to better assist in decision‐making.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KIT and stem cell factor: mast cell dependence on SCF/KIT signaling for survival and maturation
“Mast cells show exceptional dependence on SCF/c-Kit signaling for tissue survival, proliferation, migration, and terminal maturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Loss of function mutations in c-Kit or c-Kitl produce profound tissue mast-cell deficiency, and administration of SCF expands mast-cell populations in vivo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCF is widely regarded as the main growth factor for mast cells, controlling nearly every stage of mast cell biology, including progenitor differentiation, proliferation of immature and mature cells, survival through inhibition of apoptosis, chemotaxis, adhesion, and effector activation, such as degranulation and cytokine release” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCF amplifies IgE/FcϵRI-dependent mast cell activation mainly by lowering the activation threshold and enhancing downstream signaling, rather than triggering strong degranulation on its own.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MCs express the tyrosine kinase receptor c-Kit, which binds stem cell factor (SCF), a key regulator of MC differentiation, maturation, proliferation and survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCF has also been implicated in MC activation, both as a direct trigger of degranulation and as an amplifier” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the reported effects of SCF on MC mediator release are variable with some studies describing comparable levels of mediator release following SCF and anti-IgE stimulation, whereas others report a weaker response to SCF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KIT expression beyond mast cells: melanocytes, hematopoietic progenitors, germ cells, and taste cells
“These include hematopoietic progenitors, melanocytes, germ cells, and mast cells, which all are significantly affected by loss-of-function mutations of KIT or SCF” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many other cells can express KIT constitutively or during immune responses, including dendritic cells, eosinophils, ILC2 cells, and taste cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mast cell depletion through KIT as a therapeutic mechanism
“These include monoclonal antibodies and small molecules that can specifically inhibit mast cell degranulation via key receptors (such as FcεRI), that block specific signal transduction pathways involved in mast cell activation (for example, BTK), that silence mast cells via inhibitory receptors (such as Siglec-8) or that reduce mast cell numbers and prevent their differentiation by acting on the mast/stem cell growth factor receptor KIT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic urticaria (CU) is a mast cell (MC)-dependent disease with limited therapeutic options.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Current management strategies are directed at inhibiting IgE-mediated activation of MCs and antagonizing effects of released mediators.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Current recommended and effective treatment options for urticaria aim to target mast cell mediators at the receptors on nerves and endothelia, mast cell releasability, or mast cell activation by autoimmune triggers among others.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Novel treatments currently under development aim to better regulate Type 2 immunity, or silence mast cells via inhibitory receptors, or to reduce mast cell numbers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gut microbiome: emerging and unresolved role
“There is emerging evidence that changes in the gut microbiome may play a role in the pathophysiology of urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, as with the chicken or the egg dilemma, it is not clear if these changes are the cause or the consequence of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Diagnostic steps: medical history, physical examination, photographs, and basic tests
“A detailed medical history is essential in the diagnosis of urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“is the first step in the diagnostic workup of all urticaria patients. This clinical anamnesis should include concomitant and comorbid diseases. The second step is the physical examination of the patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since wheals and angioedema are transient and may not be present at the time of physical examination, it is important to review prior documentation, including patient‐provided photographs of wheals and/or angioedema” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In CU, the third step involves a basic diagnostic workup which includes a limited set of recommended diagnostic tests” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aims of the diagnostic workup in CSU: 2026 international guideline
“In CSU, the diagnostic workup has seven major aims: (i) to confirm the diagnosis and exclude differential diagnoses, especially for angioedema‐only patients; (ii) to look for the underlying causes; (iii) to identify relevant conditions that modify disease activity; (iv) to check for comorbidities; (v) to identify the consequences of CSU; (vi) to assess predictors of the course of disease and response to treatment; and (vii) to monitor disease activity, impact, and control” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Routine laboratory tests: differential blood count, CRP or ESR, total IgE, and IgG anti-TPO
“We recommend limited investigations. Basic tests include differential blood count, CRP and/or ESR, and in specialized care total IgE and IgG anti‐TPO, and more biomarkers as appropriate. We recommend performing further diagnostic measures based on the patient history and examination, especially in patients with long standing and/or uncontrolled disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The basic tests include a differential blood count, CRP and/or ESR (to rule out severe systemic disease, as an indicator for parasitic disease, eosinophilic count, autoimmune disease such as systemic lupus), in all patients. In patients under specialist care, additional tests, such as total IgE and IgG‐anti‐TPO may be performed, as they indicate the likelihood of response to omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, although a clinical association between these laboratory markers and urticaria endotypes has been demonstrated, their clinical usefulness remains limited because there are no studies evaluating their diagnostic accuracy. Currently, cutoff points can be suggested but cannot be recommended for definitive endotype classification” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intensive and costly general screening programs for causes of urticaria are not advised.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Differential diagnosis: urticarial vasculitis, autoinflammatory disorders, and bradykinin-mediated angioedema
“In patients who exclusively develop wheals (but not angioedema), urticarial vasculitis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“such as Schnitzler syndrome or cryopyrin‐associated periodic syndromes (CAPS), need to be ruled out.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the other hand, in patients who suffer exclusively from recurrent angioedema (but not from wheals), differential diagnosis should include bradykinin‐mediated angioedema, including those induced by angiotensin‐converting enzyme (ACE)‐inhibitor or gliptins, or hereditary angioedema (HAE)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limited laboratory testing: 2014 AAAAI practice parameter and international guideline tests
“However, empiric elimination diets (not guided by history and testing) and extensive laboratory evaluation are not recommended in the diagnosis of urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The limited testing that has been suggested by the international guidelines and the AAAAI Practice Parameter Update 2014 (A-PP) includes a CBC with diff, ESR or CRP, liver enzymes and TSH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay: CURE registry, 4,332 adults with chronic urticaria
“We retrospectively analysed data from CU adult patients from the international, multicenter Chronic Urticaria Registry (CURE).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 4332 CU patients, 61% had standalone chronic spontaneous urticaria (sCSU), 18% had ≥ 1 form of chronic inducible urticaria (CIndU), and 21% had a combination of both (CSU + CIndU).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnosis of CU was delayed in 24% of patients by at least 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CIndU patients showed a longer DD compared to those with sCSU or CSU + CIndU (median, [IQR]: 4, [0-22] vs. 1, [0-6] vs. 2, [0-9] months, p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In CSU patients, a DD of ≥ 6 months was associated with lower CSU activity (median weekly Urticaria Activity Score of 14 vs. 21, p = 0.02) compared to that of DD < 6 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time from symptom onset to diagnosis: 673 adults with inadequately controlled CSU
“This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) duration of disease from symptom onset to diagnosis was 24.0 (63.36) months (median 4.7 months) and from diagnosis to the time of study enrollment was 57.7 (77.79) months (median 27.7 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosing clinicians: physician-diagnosed CSU in a 2019 United States survey
“Allergists (39.8%), followed by primary care physicians (36.3%) and dermatologists (16.4%), were the most frequent diagnosticians responsible for CSU diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“UCT scores show that 77.0% of respondents had a score ≤11, indicating poorly controlled CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease activity instruments: UAS7 and AAS recommendations and score ranges
“We recommend the use of the urticaria activity score, UAS7, and/or of the angioedema activity score, AAS, for assessing disease activity in patients with chronic spontaneous urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The UAS7, calculated as the sum of daily scores over 7 consecutive days, should be routinely used to monitor disease activity and treatment response in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For CSU patients who develop angioedema, with or without wheals, the Angioedema Activity Score (AAS) should be used to assess disease activity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CSU patients who experience wheals and angioedema should use the UAS7 and the AAS in combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the UAS7 the sum of the score (0–3 for wheals +0–3 for pruritis) for each day is summarized over 1 week (7 days) for a maximum of 42.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the AAS, scores are summed up to an AAS day sum score (0–15), 7 AAS day sum scores to an AAS week sum score (AAS7, 0–105), and 4 ASS week sum scores may be summed up to an AAS 4‐week sum score (AAS28, 0–420).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Daily UAS scores for wheals and pruritus
UAS7 disease activity bands: pooled omalizumab trials, twice-daily UAS7
UAS7 minimal important difference: omalizumab trial participants
“Seventy-three subjects with CIU completed the UAS with enhanced instructions, other measures of disease activity including the size of the largest hive, and collateral measures during a multicenter, randomized, double-blind, placebo-controlled study of omalizumab for the treatment of CIU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The MID ranged from 9.5 to 10.5 for the UAS7, 5.0 to 5.5 for number of hives (weekly average), and 4.5 to 5.0 for pruritus and size of largest hive (weekly average).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One hundred thirty adult patients with chronic spontaneous urticaria completed both UAS7 versions, the Patients Global Assessment (PatGA) of disease activity, the Urticaria Control Test (UCT), the Chronic Urticaria Quality of Life Questionnaire, and the Dermatology Life Quality Index before and after the initiation of omalizumab therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The MID was 11 for the UAS7 (SDC = 12) and 12 for the UAS7TD (SDC = 11).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disease control instruments: UCT and AECT recommendations and cutoffs
“We recommend the use of the urticaria control test, UCT, and/or the angioedema control test, AECT, for assessing disease control in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The UCT cutoff value for well‐controlled disease is 12 out of 16 possible points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two versions of the AECT exist, one with a 4‐week recall period and one with a 3‐month recall period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The AECT consists, like the UCT, of only four questions. Its cut off for well controlled disease is 10 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients who are in the range of UCT 12–15, therefore a step up might also be required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment goal of complete control: UAS of 0 and UCT of 16
“The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
UCT development, score range, and cutoff of 12 for controlled disease
UCT minimal important difference: 65 adults with difficult-to-treat CSU
AECT development and cutoff of 10 for well-controlled recurrent angioedema
“A 4-item AECT with recall periods of 4 weeks and 3 months was developed based on 106 potential items tested in 97 patients with mast cell mediator-induced (n = 49) or bradykinin-mediated recurrent AE (n = 48).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A stratification of AECT scores into different levels of disease control together with a receiver-operating characteristic curve analysis suggested a cutoff value of 10 or more points to identify patients with well-controlled RA versus less than 10 points to identify patients with poorly controlled disease for both AECT versions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AECT minimal clinically important difference
“Patients with recurrent angioedema due to chronic spontaneous urticaria, hereditary angioedema, or acquired C1‐inhibitor deficiency were repeatedly asked to complete the AECT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MCID was found to be three points for improvement of angioedema control.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AAS development and validation in recurrent angioedema
“Recurrent angioedema (RecA) is a frequent clinical problem characterized by suddenly occurring cutaneous and/or mucosal swellings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, data from 110 and 80 RecA patients were used during the AAS item evaluation and validation phase, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The resulting AAS consisted of five items and was found to have a one-dimensional structure and excellent internal consistency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Wheals: definition in the 2026 international guideline
“Urticaria is a condition characterized by the development of wheals (hives), angioedema or both. A wheal has three typical features: a sharply circumscribed superficial central swelling of variable size and shape, almost invariably surrounded by reflex erythema, an itching or sometimes burning sensation, a fleeting nature, with the skin returning to its normal appearance, usually within 30 min to 24 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Angioedema: definition in the 2026 international guideline
“Angioedema is characterized by: a sudden, pronounced erythematous or skin colored deep swelling in the lower dermis and subcutis or mucous membranes, tingling, burning, tightness, and sometimes pain rather than itch, a resolution slower than that of wheals (can take up to 72 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Angioedema frequency and symptoms: 673 adults with inadequately controlled CSU
“According to medical records, 58.5% (394 of 673) patients were reported to have had CSU‐associated angioedema, and 41.0% (276 of 673) had experienced CSU‐associated angioedema within the past 12 months from inclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to the patient survey, 65.8% of patients (427 of 649) reported experiencing angioedema during the previous 12 months; of these, 75.2% (321 of 427) reported having experienced angioedema within the past 4 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with angioedema reported on a scale of 0‐10 the amount of itching (mean [SD] 7.2 [2.16]), swelling (7.3 [2.73]), and pain (5.4 [3.39]) they experienced during a typical episode over the past 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Angioedema reporting in medical records and patient reports: 673 participants
“This international observational study assessed 673 patients with inadequately controlled chronic spontaneous urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among evaluable patients, 259 (40.3%), 173 (26.9%) and 211 (32.8%) were in the Yes‐angioedema , No‐angioedema and Misaligned category, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Angioedema in the past 3 months: physician-diagnosed CSU in a 2019 United States survey
Itch: pruritus as a key symptom and its effect on daily life and work
“It captures the two key signs and symptoms of urticaria—wheals and pruritus—based on daily self‐assessments by the patient” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Its debilitating symptoms—severe pruritus and wheals—disruption of daily activities, sleep, and emotional well‐being can create a cycle of frustration and decreased quality of life (QoL) often worsened by comorbidities such as anxiety and depression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sleep: interference with sleep and claims for sleep-related conditions
“Chronic spontaneous urticaria markedly interfered with sleep and daily activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adults (≥18 years) with CSU in the US HealthVerity claims database were included (January 2016-October 2023).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 224,958 patients were included (mean follow-up: 2.4 years). The proportion of patients with claims for sleep-related conditions increased from baseline to follow-up (8.8% vs 15.4%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“a higher proportion of patients with uncontrolled vs controlled disease had ≥1 claim for sleep-related (17.3% and 13.4%) and MH conditions (60.6% and 51.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Comorbidities and consequences of CSU: 2026 international guideline
“In CSU, the most common comorbidities are CIndUs, autoimmune diseases, metabolic syndrome, and allergies. Mental disorders, such as depression and anxiety, sexual dysfunction and sleep disturbance are also common consequences of CSU” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Autoimmune thyroid disease: systematic review
“There is a strong link between CSU and elevated levels of IgG antithyroid autoantibodies (AAbs), with most of a large number of studies reporting rates of ≥10%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thyroid dysfunction rates are increased in patients with CSU (strong evidence). Hypothyroidism and Hashimoto's thyroiditis are more common than hyperthyroidism and Graves' disease (strong evidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thyroid dysfunction is more common in adult patients with CSU than in children (strong evidence) and in female than in male patients with CSU (weak evidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Thyroid and other autoimmune diseases: 12,778 participants with chronic urticaria in Israel
“Data on 12,778 patients given a diagnosis of CU by either allergy or dermatology specialists during 17 years in a large health maintenance organization in Israel were collected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Having CU was associated with an increased odds ratio for hypothyroidism, hyperthyroidism, and antithyroid antibodies. Female patients with CU had a significantly higher incidence of rheumatoid arthritis, Sjögren syndrome, celiac disease, type I diabetes mellitus, and systemic lupus erythematosus, mostly diagnosed during the 10 years after the diagnosis of CU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other autoimmune diseases: systematic review of prevalence
“The prevalence of individual AIDs in CSU is increased (≥1% in most studies vs ≤1% in the general population).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The rates of comorbidity in most studies were ≥1% for insulin-dependent diabetes mellitus, rheumatoid arthritis (RA), psoriasis and celiac disease (CD), ≥2% for Graves' disease, ≥3% for vitiligo, and ≥5% for pernicious anemia and Hashimoto's thyroiditis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CSU patients have an increased risk of AIDs, especially adult female patients and those with a positive family history and a genetic predisposition for AIDs, who should be screened for signs and symptoms of AIDs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric disorders: systematic review and meta-analysis
“Twenty-five studies were identified. Almost one out of three CU patients have at least one underlying psychiatric disorder. None of the studies clarified whether the psychiatric disorders pre-existed the CU onset, and no association was found between CU severity and duration, and psychological functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After meta-analyzing these three studies, among 177,998 CU patients, 56,258 had psychiatric comorbidity (31.61%). Among 996,446 healthy individuals (control group), 45,471 were found to suffer from at least one psychiatric disorder (4.6%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most prevalent were found to be sleep–wake disorders (36.7%), followed by anxiety disorders (30.6%), mood disorders (29.4%), trauma and stressor-related disorders (17.3%), somatic symptom and related disorders (17.2%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mental health conditions: United States claims before and after CSU diagnosis
“Adults (≥18 years) with CSU in the US HealthVerity claims database were included (January 2016-October 2023).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 224,958 patients were included (mean follow-up: 2.4 years). The proportion of patients with claims for sleep-related conditions increased from baseline to follow-up (8.8% vs 15.4%), and for MH conditions (40.6% vs 56.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Claims for sleep-related and MH conditions increased after CSU diagnosis, particularly among patients with uncontrolled disease” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Suicidal ideation and malignant neoplasms: hazard ratios compared with controls
Corticosteroid-associated adverse events: United States claims cohort of 200,298 participants
“This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users. The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When assessed according to corticosteroid user type, lipid disorders were the most common AE among patients in the ≤ 31D group (33.0%), and hypertension was the most frequent in the > 31 to ≤ 60D, > 60D, and ≥ 90Dc groups (38.0%, 44.0%, and 49.4%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportions of patients who reported skeletal conditions and avascular necrosis were ≥ 3 times higher in the ≥ 90Dc group versus non-users.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prolonged systemic corticosteroid use: 2026 international guideline
“If systemic corticosteroids are used, doses between 20–50 mg/day of prednisone equivalent are needed (dose is appropriate for adults and not children). Because such high doses will have side effects over the long term, we strongly recommend against the prolonged use of corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend against the long‐term use of systemic glucocorticosteroids or depot preparations in CU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Chronic spontaneous urticaria
Humanistic burden and health-related quality of life
Quality of life, sleep, and work impairment in adults with CSU persisting 12 months or more despite treatment, Novartis-funded
“This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Almost 50% of patients had moderate‐to‐severe disease activity as reported by Urticaria Activity Score. Mean (SD) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1 (6.62) and 33.6 (20.99), respectively. Chronic spontaneous urticaria markedly interfered with sleep and daily activities. Angioedema in the previous 12 months was reported by 66% of enrolled patients and significantly affected HRQoL. More than 20% of patients reported ≥1 hour per week of missed work; productivity impairment was 27%. These effects increased with increasing disease activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EQ‐5D‐3L domains for which patients most frequently reported moderate or extreme problems were pain/discomfort (63.2% of patients), anxiety/depression (47.4%), and usual activities (34.2%) (Figure 3C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean DLQI scores in this study suggest that CSU has a moderate impact on patients’ HRQoL,35 which is greater than previously thought; further, more than 40% had DLQI scores of 10 or greater, which, in psoriasis, justifies the initiation of a biologic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Novartis Pharma AG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adults with self-reported physician-diagnosed CSU, 2019 National Health and Wellness Survey: utilities, DLQI, anxiety, depression, and work impairment, Novartis-funded
“Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) SF-6D and EQ-5D health utility scores were 0.54 (0.14) and 0.62 (0.34), respectively. The mean (SD) DLQI score was 13.8 (11.2), with more than 74.0% of respondents reporting anxiety (GAD-7 ≥5) and depression (PHQ-9 ≥5). Mean percent (SD) scores for absenteeism, presenteeism, overall work impairment, and activity impairment were 36.5% (26.1), 67.2% (34.9), 73.1% (34.2), and 62.6% (34.1), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) DLQI score was 13.8 (11.2), with 54.2% of respondents having a score >10. More than one-third (36.5%) of respondents had a DLQI score between 21 and 30, indicating an extremely large effect on the patient's life (Fig. 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSU compared with atopic dermatitis and psoriasis, 2019 US National Health and Wellness Survey
“This retrospective, cross-sectional study used real-world data from adult respondents from the 2019 US National Health and Wellness Survey (NHWS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (standard error [SE]) MCS and PCS scores were lower (worse) among respondents with physician-diagnosed CSU vs. AD and PSO, respectively: MCS: 41.3 (0.6) vs. 44.8 (0.5) vs. 45.3 (0.2); PCS: 42.1 (0.5) vs. 47.8 (0.4) vs. 47.7 (0.2); all p < 0.001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents with CSU reported higher (p < 0.001) work and activity impairment and HCRU vs. respondents with AD or PSO.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chronic urticaria compared with psoriasis in France, Germany, Italy, Spain, and the United Kingdom, supported by Novartis and Genentech
“This retrospective cross‐sectional analysis compared data from adult patients with chronic urticaria (CU), used as a proxy for CSU, and PsO from the National Health and Wellness Survey in France, Germany, Italy, Spain and the United Kingdom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis included 769 CU and 7857 PsO (26.9% moderate/severe) patients. Following adjustment for covariates, CU patients showed a greater health‐related quality of life (HRQoL) impairment vs. overall PsO (MCS: −2.4, PCS: −1.6, SF‐6D: −0.03; all P < 0.001). CU patients showed a higher risk of anxiety, depression and sleep difficulties [odds ratio (OR): 1.63, 1.34 and 1.56, respectively; all P < 0.01] and greater healthcare resource use vs. overall PsO.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Burden of illness in CU is higher than PsO of all severities but similar to that observed in moderate/severe PsO.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was supported by Novartis Pharma AG, Basel, Switzerland, and Genentech, Inc., South San Francisco, CA, USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported burden by disease control in a multinational online survey, Novartis-funded
“A multinational, cross-sectional online survey was completed by patients with chronic urticaria (CU) and physicians treating CU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 582 patients with CSU (62% women; mean [standard deviation, SD] age: 42.2 [11.9] years) completed the online survey. Patients reported a mean (SD) diagnostic delay of 2 (5.4) years and saw 6.1 (8.9) physicians. The majority (79%) of patients were on antihistamines, of which 84% were inadequately controlled (UCT score of < 12) and reported a significantly higher negative impact of CSU on the HRQoL domains than adequately controlled patients, with the highest impact on mental and emotional well-being and social life and intimate relationships. More than half (55%) of the patients experienced angioedema with a mean (SD) of 7.7 (14.0) episodes per year. In addition, sleeping problems (62%), pain (55%) and fatigue (49%) were frequently reported physical symptoms during an exacerbation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study, and the journal’s Rapid Service and Open Access Fees, were funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sex and age differences in angioedema, sleep disturbance, and quality of life in the CURE registry
“We analysed Chronic Urticaria Registry (CURE) data, an international real‐world registry for patients with chronic urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with males, females showed higher rates of angioedema (59.6 vs. 51.7%; p < 0.001), systemic symptoms (34.6 vs. 25.4%; p < 0.001), sleep disturbance (38.9 vs. 32.5%; p < 0.001), QoL impairment (CU‐Q2oL score 32 vs. 27.7; p < 0.001) and lower rates of urticaria control than males in all medication categories (p < 0.05 for all).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The disease was especially more burdensome and refractory in females aged 51–65 years than males, evidenced by more angioedema and systemic symptoms, worse QoL, lower UCT scores and more emergency visits (p < 0.05 for all).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life of chronic urticaria outpatients on the Nottingham health profile
“One hundred and forty-two out-patients completed self-administered questionnaires: a disease-specific, purpose designed questionnaire, and the Nottingham health profile (NHP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The NHP part I scores showed restriction in the areas of mobility, sleep, energy, and demonstrated pain, social isolation and altered emotional reactions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Review of the global burden of chronic urticaria: quality of life, anxiety and depression, and work
“Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CU may have a strong impact on health-related quality of life (HRQoL), particularly when CSU is associated with angio-oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Severe pruritus and the unpredictable occurrence of weals and angio-oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients' performance at school and work (6% absenteeism and 25% presenteeism).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Narrative review of the overall burden of CSU
“This narrative review synthesizes current evidence on the overall burden of CSU, encompassing epidemiology, clinical manifestations, humanistic impact, cumulative life course impairment, and economic costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CSU markedly disrupts quality of life through sleep disturbance, pruritus, emotional distress, psychiatric comorbidity, impaired social and occupational functioning, and stigma, with effects extending to children, caregivers, and family members.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Annual healthcare costs and resource use in a commercially insured US population, research paid by Genentech
“The prevalence of chronic idiopathic or spontaneous urticaria is 0.11 % in a commercially insured US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral corticosteroids were the most commonly prescribed medication, used in 54.7 % of patients. Patients accumulated a mean of 15.1 office visits per year (standard deviation 12.6). The mean all-cause healthcare cost totaled over US$9000 per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean all-cause healthcare costs were US$9142 (SD US$21,835, median US$3659) (Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean urticaria-related costs were US$997 (SD US$2322, median US$612).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“M.S. Broder and E. Chang are employed by Partnership for Health Analytic Research, LLC, a health services research company paid by Genentech, Inc. to conduct this research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled CSU, resource use, and costs in US HealthVerity claims
“Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 200,298 patients were followed-up for a median of 2.3 years after diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Corticosteroids were the most prescribed treatment during follow-up among the 166,195 patients prescribed at least 1 treatment (94.3%). Proxy events were observed in 59.1% of the patients. HCRU and health care costs increased from baseline in patients with uncontrolled CSU during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of patients with CSU who were prescribed treatment, more than 50% experienced uncontrolled CSU, which was associated with increased HCRU and health care costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systemic corticosteroid use, adverse events, and resource use in US HealthVerity claims, Novartis-funded
“This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More frequent HCRU may also have additional implications for health care costs, which are not discussed here.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study and article publication, including the journal’s Rapid Service Fee, was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual direct and indirect costs in 50 adults at allergy and dermatology clinics
“The Johns Hopkins University allergy and dermatology ambulatory clinics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty adults with active CIU were recruited in sequential order.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with CIU consumed a mean (SD) of $2047 ($1483) annually. Because CIU is primarily an outpatient disease, medication costs alone accounted for 62.5% ($1280) of the total annual cost. Indirect costs accounted for 15.7% ($322) of the total costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ASSURE-CSU: direct, indirect, and out-of-pocket costs by country and resource use
“Total average (SD) annual direct costs per patient per year, as captured in the retrospective medical record review, ranged from PPP$907.1 ($2431.14) in Italy to PPP$2984.2 ($8969.46) in France. The major drivers of these costs were therapies (range, PPP$426.4‐$1788.7) and inpatient visits (range, PPP$250.7‐$1074.4) (Tables S5 and S6 in Appendix S5 and S6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Average indirect costs, or costs of patient‐reported total work productivity loss over 4 weeks, were driven primarily by the cost of presenteeism (range, PPP$544.5‐$1180.0); the mean (SD) cost of work productivity loss ranged from PPP$544.8 ($603.22) in France to PPP$1287.4 ($1123.80) in Germany (Table S7 in Appendix S7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, in ASSURE‐CSU, CSU‐related out‐of‐pocket expenses to patients averaged nearly PPP$500 per year and approached PPP$1000 in Canada.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 97 patients (14.4%) with at least one CSU‐related ED visit in the past 12 months, the annual mean (SD) number of visits was 1.8 (1.26). Hospitalization for CSU was recorded for 55 patients (8.2%), with a mean (SD) length of stay per hospitalization of 3.7 (2.67) days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-reported all-cause resource use over 6 months, 2019 National Health and Wellness Survey
“Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of all-cause HCRU, 96.5% of the respondents had visited any healthcare provider in the past 6 months, and 60.2% reported visiting an emergency department a mean (SD) of 8.6 (11.9) and 3.7 (5.0) times, respectively. Meanwhile, 55.9% of respondents had been hospitalized in the past 6 months, with the mean (SD) number of hospitalizations being 4.4 (9.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Review of the global burden of chronic urticaria: treatment and total cost ranges
“Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab spending in Oregon all-payer claims, all indications, 2024
Cost of routine laboratory screening in adults with CSU: US simulation
“Average laboratory costs per simulated patient with CSU were $573 (standard deviation [SD], $41), with only 0.16% (SD, 3.99%) of tests resulting in improved clinical outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From a simulated US population perspective, nation-wide screening costs could reach $941,750,741 to $1,833,501,483.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Chronic spontaneous urticaria on families
Family quality of life and household expenses by disease activity and control, international UCARE study
“This international cross‐sectional study was conducted in 12 countries across three continents, from January to December 2024 at Urticaria Centres of Reference and Excellence (UCARE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 1187 CSU patients and their respective family members completed questionnaires, including the Family Dermatology Life Quality Index (FDLQI), and physicians also provided clinical data on disease severity and control.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FDLQI had a mean total score of 9.6 and mean scores varied across countries (Figure 1, Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When stratified by UAS7 severity (minimal activity, mild, moderate, severe), family members of patients with higher disease activity reported significantly greater emotional distress, physical burden, social limitations and financial strain (Figure 3, Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Household expenses showed no statistically significant association with either severity (β = 0.27; CI95% –0.47 to 1.00) or control (β = −0.23; CI95% –0.53 to 0.06).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare costs in Medicaid-enrolled children younger than 12 years
“Medicaid claims from four states (09/01/2013–03/31/2016) were used to identify patients less than 12 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 548 CIU/CSU patients (mean [SD] age 4.5 [3.3] years; 51.3% male) were matched 1:1 with controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, CIU/CSU patients also had significantly higher PPPY healthcare costs (mean cost difference [MCD] $1853), driven by incremental outpatient (MCD $1286) costs (all p values < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CIU/CSU adversely affects lives of pediatric patients and their caregivers, leading to school absenteeism, reduced school performance, and more days off work [9].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare costs in commercially insured children younger than 12 years
“To describe treatment patterns, health care resource utilization (HRU), and costs in pediatric patients with CIU/CSU (<12 years old) and to compare these with pediatric patients without CIU/CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A commercial administrative claims data base (September 2013 to June 2016) was used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 6109 pediatric patients with CIU/CSU were selected, and 6107 were 1:1 matched with controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to the controls, the patients with CIU/CSU had higher rates of HRU (incidence rate ratios of 1.71, 2.39, and 2.07 for inpatient, emergency department, and outpatient visits, respectively; all p < 0.01), and higher all-cause per patient per year costs (mean cost differences of $2090, $1606, and $483 for total, medical, and pharmacy costs, respectively; all p < 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Not applicable.
Approaches to treatment
Current treatment options and standard of care
Second-generation h1 antihistamines
First-line standard-dose second-generation H1-antihistamine: 2026 international guideline
“We recommend a 2nd generation H1‐antihistamine as first‐line treatment for all types of urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most, but not all 2nd generation H1‐antihistamines have been tested specifically in urticaria, and evidence supports the use of bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine, and rupatadine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend the use of a standard‐dosed modern 2nd generation H1‐antihistamines as the first‐line symptomatic treatment for urticaria. However, no recommendation can be made on which to choose because, to date, well‐designed clinical trials directly comparing the efficacy and safety of all modern 2nd generation H1‐antihistamines in urticaria are largely lacking.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest 2nd generation H1‐antihistamines to be taken regularly for the treatment of patients with chronic spontaneous urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Updosing up to four-fold as second-line treatment: 2026 international guideline
“We recommend updosing of a 2nd generation H1‐antihistamine up to 4‐fold in patients with chronic urticaria unresponsive to a standard‐dosed 2nd generation H1‐antihistamines as second‐line treatment before other treatments are considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend against using higher than 4‐fold standard dosed H1‐antihistamines in chronic urticaria” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients need to be informed that 2nd generation H1‐antihistamine updosing is off‐label and higher than fourfold is not recommended as it has not been tested.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For updosing, also the time of onset needs to be considered, for example, for treatment with an antihistamine, further improvement cannot be expected after 1–2 weeks of treatment as receptor saturation is complete after 1 week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-generation H1-antihistamines and combinations of antihistamines: 2026 international guideline
“The older 1st generation H1‐antihistamines have pronounced anticholinergic and sedative effects and many interactions with alcohol and other drugs such as analgesics, hypnotics, sedatives, and mood elevating drugs, have been described.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we recommend against their use for the routine management of CU as first‐line agents” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest against using different H1‐antihistamines at the same time (against an updosing of a single H1‐antihistamine if not legally restricted in country)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Leukotriene receptor antagonists as add-on therapy: 2026 international guideline
“In general, the level of evidence for the efficacy of leukotriene receptor antagonists in urticaria is low, but the most so far for montelukast.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A recent, systematic review and meta‐analysis found that adding leukotriene receptor antagonists to H1 antihistamines provides modest reductions in urticaria activity without significantly increasing overall adverse events, though the risk of neuropsychiatric effects remains uncertain” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Draft 2026 AAAAI/ACAAI Joint Task Force guideline: review invitation and scope
Dose-response network meta-analysis of 211 randomized trials for the Joint Task Force guideline update
Montelukast and H2 blocker adjuncts to a second-generation antihistamine: urticaria activity
Sedation by agent and dose
Implications for guidelines and payers of diminishing benefit beyond a standard dose
Response to updosing among standard-dose nonresponders: systematic review and meta-analysis
“The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 1042 articles and 15 articles were included in the final evaluation. We performed two meta-analyses, one that included studies that analysed treatment response among groups receiving different antihistamine dosages vs. placebo, and another that analysed antihistamine updosing in those patients who did not respond to standard dosages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only five articles obtained a high quality level score. We did not find significant differences in response rates or number of weals in those patients who received a standard dosage vs. a high dosage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated relative risk for improvement by increasing the antihistamine dosage was 2·27 [95% confidence interval (CI) 1·68-3·06]; however, there was significant heterogeneity. The proportion of nonrespondent patients with CSU who responded to antihistamine updosing was 63·2% (95% CI 57-69·6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled disease at Month 24 on non-sedating and updosed antihistamines: AWARE real-world study, sponsored by the omalizumab manufacturer
“AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Anti-IgE monoclonal antibodies
Omalizumab as add-on treatment after high-dose antihistamines: 2026 international guideline
“We recommend adding on omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for the treatment of patients with CU unresponsive to high doses of 2nd generation H1‐antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The recommended initial dose in CSU is 300 mg every 4 weeks as add on to antihistamine treatment. Dosing is independent of total serum IgE and bodyweight” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies support the use of omalizumab treatment at doses up to 600 mg and intervals of 2 weeks, in patients with insufficient response to standard dosed omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients need to be informed that omalizumab updosing is off‐label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drug survival studies, or time to discontinuation, for omalizumab show that the main reason for discontinuation is due to well‐controlled disease and far less due to ineffectiveness or adverse effects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-approved indication and dosage in chronic spontaneous urticaria: omalizumab
Anaphylaxis warning: omalizumab
Adverse reactions in pooled CSU trials, Day 1 to Week 12: omalizumab
| Adverse reaction | Omalizumab 150 mg (n=175) | Omalizumab 300 mg (n=412) | Placebo (n=242) |
|---|---|---|---|
| Nausea | “2 (1.1%)” | “11 (2.7%)” | “6 (2.5%)” |
| Nasopharyngitis | “16 (9.1%)” | “27 (6.6%)” | “17 (7.0%)” |
| Sinusitis | “2 (1.1%)” | “20 (4.9%)” | “5 (2.1%)” |
| Upper respiratory tract infection | “2 (1.1%)” | “14 (3.4%)” | “5 (2.1%)” |
| Arthralgia | “5 (2.9%)” | “12 (2.9%)” | “1 (0.4%)” |
| Headache | “21 (12.0%)” | “25 (6.1%)” | “7 (2.9%)” |
| Cough | “2 (1.1%)” | “9 (2.2%)” | “3 (1.2%)” |
Week 12 itch severity, hive count, and UAS7=0 in CSU Trial 1: omalizumab label
| Week 12 outcome | Omalizumab 75 mg | Omalizumab 150 mg | Omalizumab 300 mg | Placebo |
|---|---|---|---|---|
| N | “77” | “80” | “81” | “80” |
| Weekly itch severity score, mean change (SD) | “−6.46 (6.14)” | “−6.66 (6.28)” | “−9.40 (5.73)” | “−3.63 (5.22)” |
| Weekly itch severity score, difference in LS means vs placebo | “−2.96” | “−2.95” | “−5.80” | Not applicable |
| Weekly hive count score, mean change (SD) | “−7.36 (7.52)” | “−7.78 (7.08)” | “−11.35 (7.25)” | “−4.37 (6.60)” |
ASTERIA I: well-controlled UAS7 ⩽6 and complete response UAS7=0 with omalizumab 300 mg
“ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1 antihistamine treatment at licensed doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The omalizumab 300-mg group met all nine secondary end points, including a significant decrease in the duration of time to reach minimally important difference response (⩾5-point decrease) in weekly ISS ( P <0.0001) and higher percentages of patients with well-controlled symptoms (urticaria activity score over 7 days (UAS7) ⩽6: 51.9% vs. 11.3% P <0.0001) and complete response (UAS7=0: 35.8% vs. 8.8% P <0.0001) versus placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 12 itch severity by omalizumab dose: phase 3 randomized trial
“In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of omalizumab in patients with moderate-to-severe chronic idiopathic urticaria who remained symptomatic despite” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We randomly assigned 323 patients to receive three subcutaneous injections, spaced 4 weeks apart, of omalizumab at doses of 75 mg, 150 mg, or 300 mg or placebo, followed by a 16-week observation period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, the mean (±SD) change from baseline in the weekly itch-severity score was -5.1±5.6 in the placebo group, -5.9±6.5 in the 75-mg group (P=0.46), -8.1±6.4 in the 150-mg group (P=0.001), and -9.8±6.0 in the 300-mg group (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The frequency of serious adverse events was low, although the rate was higher in the 300-mg group (6%) than in the placebo group (3%) or in either the 75-mg or 150-mg group (1% for each).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Week 12 results with omalizumab 300 mg after antihistamines up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists
| Week 12 outcome | Omalizumab 300 mg (n = 252) | Placebo (n = 83) |
|---|---|---|
| Change from baseline in UAS7, mean (95% CI) | “−19.0 (−20.6 to −17.4)” | “−8.5 (−11.1 to −5.9)” |
| UAS7 ≤6, no. (%) | “132 (52.4)” | “10 (12.0)” |
| UAS7 = 0, no. (%) | “85 (33.7)” | “4 (4.8)” |
Pooled randomized trial effects of omalizumab 150 mg and 300 mg: systematic review
“This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95%CI -12.87 to -9.24), the ISS7 (MD -4.45; 95%CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5; 95%CI -7.75 to -2.25)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world effectiveness and adverse events: meta-analysis of 67 observational studies
“Included studies were observational in design and included at least 1 outcome in common with other studies and at a concurrent time point of exposure to omalizumab. A total of 67 articles (35.2% of those screened) were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Random-effects meta-analyses were performed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Omalizumab therapy was associated with an improvement in UAS7 scores (−25.6 points, 95% CI, −28.2 to −23.0; P < .001; 15 studies, 294 patients), an improvement in UAS scores (−4.7 points, 95% CI, −5.0 to −4.4, P < .001; 10 studies, 1158 patients), an average complete response rate of 72.2% (95% CI, 66.1%-78.3%; P < .001; 45 studies, 1158 patients) with an additional average partial response rate of 17.8% (95% CI, 11.7%-23.9%; P < .001; 37 studies, 908 patients), and an average adverse event rate of 4.0% (95% CI, 1.0%-7.0%; P < .001; any level of severity, 47 studies, 1314 patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drug survival and reasons for discontinuation: meta-analysis of 8 observational studies
“Observational clinical studies that reported on time to discontinuation or drug survival outcomes for omalizumab in patients with CU were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight studies comprising 4516 patients with CU (3167 female individuals [70.1%]; 3276 with chronic spontaneous urticaria [CSU]) were included. The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%). Early discontinuation was primarily due to well-controlled disease. Discontinuation due to adverse events was uncommon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update
Omalizumab 300 mg compared with dupilumab and remibrutinib: network meta-analysis of 15 studies
“This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Frequentist random-effects network meta-analysis were conducted in R.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lower omalizumab doses lacked durability at 24 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ligelizumab not superior to omalizumab: PEARL-1 and PEARL-2 phase 3 trials
“PEARL-1 and PEARL-2 were identically designed randomised, double-blind, active-controlled and placebo-controlled parallel-group studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between Oct 17, 2018, and Oct 26, 2021, 2057 adult patients were randomly allocated across both studies (72 mg ligelizumab n=614; 120 mg ligelizumab n=616; 300 mg omalizumab n=618, and placebo n=209).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both doses of ligelizumab were superior to placebo (p<0·0001), but not to omalizumab, in both studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase 3 PEARL studies, ligelizumab demonstrated superior efficacy versus placebo but not versus omalizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab biosimilar omalizumab-igec: FDA-approved indication in chronic spontaneous urticaria
Biosimilar CT-P39 compared with reference omalizumab: randomized active-controlled phase 3 equivalence trial
“This double‐blind, randomized, active‐controlled Phase 3 study ( NCT04426890 ) included two 12‐week treatment periods (TPs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In TP1, 619 patients were randomized (CT‐P39 300 mg, n = 204; ref‐OMA 300 mg, n = 205; CT‐P39 150 mg, n = 107; ref‐OMA 150 mg, n = 103). Equivalence was demonstrated between CT‐P39 300 mg and ref‐OMA 300 mg for mean change from baseline in ISS7 at week 12” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary efficacy, quality of life, pharmacokinetic, safety, and immunogenicity outcomes were comparable between groups at a given dose level, with no evident impact of switching.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-IL-4 receptor alpha monoclonal antibodies
Dupilumab as add-on treatment after high-dose antihistamines: 2026 international guideline
“We suggest using dupilumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“as add‐on treatment for patients with CSU unresponsive to high doses of 2nd generation H1‐antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results of Phase 3 studies show the efficacy of dupilumab as add‐on treatment, which is however, likely to be less pronounced than those observed with omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, urticaria‐specific long‐term safety data are lacking, but existent studies in various diseases reflect a generally favorable safety profile” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Available data shows efficacy regardless of low baseline IgE levels for dupilumab, which is different compared to omalizumab where very low IgE values are often a reason for insufficient response” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-approved indication in chronic spontaneous urticaria, ages 2 years and older: dupilumab
Dosage in chronic spontaneous urticaria by age and body weight: dupilumab
| Age and body weight | Initial loading dose | Subsequent dosage |
|---|---|---|
| 2 to 5 years, 5 to less than 15 kg | Not applicable | “200 mg (one 200 mg injection) every 4 weeks (Q4W)” |
| 2 to 5 years, 15 to less than 30 kg | Not applicable | “300 mg (one 300 mg injection) every 4 weeks (Q4W)” |
| 6 to 17 years, 15 to less than 30 kg | “600 mg (two 300 mg injections)” | “300 mg every 4 weeks (Q4W)” |
| 6 to 17 years, 30 to less than 60 kg | “400 mg (two 200 mg injections)” | “200 mg every 2 weeks (Q2W)” |
| 6 to 17 years, 60 kg or more | “600 mg (two 300 mg injections)” | “300 mg every 2 weeks (Q2W)” |
CUPID Study A and Study C in anti-IgE-naive participants: Week 24 efficacy in the label
| Week 24 outcome | Study A dupilumab (N=68) | Study A placebo (N=68) | Study A difference or odds ratio (95% CI) | Study C dupilumab (N=73) | Study C placebo (N=75) | Study C difference or odds ratio (95% CI) |
|---|---|---|---|---|---|---|
| ISS7, LS mean change (SE) | “-10.44 (0.92)” | “-6.02 (0.94)” | “-4.42 (-6.84, -2.01)” | “-8.50 (1.39)” | “-6.13 (1.38)” | “-2.37 (-4.48, -0.27)” |
| UAS7, LS mean change (SE) | “-20.99 (1.77)” | “-11.95 (1.81)” | “-9.04 (-13.68, -4.40)” | “-15.61 (2.62)” | “-11.27 (2.61)” | “-4.34 (-8.31, -0.36)” |
| UAS7 ≤6, n (%) | “32 (47.1)” | “16 (23.5)” | “3.23 (1.43, 7.27)” | “29 (39.7)” | “17 (22.7)” | “3.05 (1.32, 7.02)” |
| UAS7 = 0, n (%) | “22 (32.4)” | “9 (13.2)” | “3.09 (1.24, 7.69)” | “22 (30.1)” | “13 (17.3)” | “2.73 (1.15, 6.50)” |
CUPID Study B in anti-IgE inadequate responders or intolerant participants: primary endpoint not met
LIBERTY-CSU CUPID Study A and Study B: phase 3 publication
“In LIBERTY-CSU CUPID Study A, patients were omalizumab-naive (n = 138, aged ≥6 years). In Study B, patients were omalizumab-intolerant/incomplete responders (n = 108, aged ≥12 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In Study A, UAS7 and ISS7 improved with dupilumab versus placebo (difference -8.5 [95% CI, -13.2 to -3.9; P = .0003] and -4.2 [95% CI, -6.6 to -1.8; P = .0005]). In Study B, tested at α = 0.043 after interim analysis, UAS7 improved (difference -5.8 [95% CI, -11.4 to -0.3; P = .0390]), with a numerical trend in ISS7 (difference -2.9 [95% CI, -5.7 to -0.07; nominal P = .0449, not significant]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although the primary end point for Study B was not met, dupilumab effects were small in patients who were omalizumab-intolerant/incomplete responders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions in pooled CUPID Studies A, B, and C and immunogenicity in CSU: dupilumab
| Pooled CUPID Study A, B, and C | Dupilumab 200 mg or 300 mg Q2W (N=195) | Placebo (N=197) |
|---|---|---|
| Injection site reactions, n (%) | “20 (10.3)” | “16 (8.1)” |
| CSU population and regimen | Positive anti-drug antibody | Persistent anti-drug antibody | Neutralizing antibody |
|---|---|---|---|
| Adults and 12 years or older, 200 mg Q2W or 300 mg Q2W through 24 weeks | “9/193 (5%)” | “1/193 (1%)” | “2/9 (22%)” |
Efficacy by baseline serum IgE level: dupilumab
“Dupilumab treatment improved ISS7, UAS7, and HSS7 over 12 and 24 weeks, regardless of baseline serum IgE level (interaction p ≥ 0.59 for all treatment by subgroup comparisons), with weak correlations ( r < 0.2) observed between IgE level changes and ISS7, UAS7, and HSS7 outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the current analysis, baseline total IgE had no predictive value as a dupilumab treatment response biomarker in CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dupilumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update
Dupilumab compared with omalizumab and remibrutinib: network meta-analysis of 15 studies
“This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Frequentist random-effects network meta-analysis were conducted in R.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen studies (4,913 patients) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Dupilumab provided sustained itch relief but delayed efficacy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Matching-adjusted indirect comparison of omalizumab with dupilumab: analysis with Genentech involvement
“To overcome this limitation, we used matching-adjusted indirect comparison to assess the efficacy of omalizumab versus dupilumab in primary phase 3 trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled patient-level data from the omalizumab ASTERIA I/II trials ( NCT01287117 /01292473) were compared with published aggregate data from the dupilumab LIBERTY-CSU CUPID Study A trial ( NCT04180488 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Improvements in both disease activity and itch severity were statistically significantly greater for omalizumab versus dupilumab (least squares mean [95% confidence interval] difference: UAS7, −7.6 [−13.0, −2.2], P = .006; ISS7, −3.0 [−5.8, −0.3], P = .031).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Genentech Inc was involved in the study design, data analysis, and preparation of the report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bruton tyrosine kinase inhibitors
Remibrutinib: FDA-approved indication, dosage, and surgical interruption
Remibrutinib: mechanism of action
REMIX-1 and REMIX-2: design and Week 12 efficacy in the prescribing information
| Outcome at Week 12 | REMIX-1 remibrutinib (N = 309) | REMIX-1 placebo (N = 153) | REMIX-2 remibrutinib (N = 297) | REMIX-2 placebo (N = 153) |
|---|---|---|---|---|
| LS mean (SE) change in ISS7 | “-9.52 (0.34)” | “-6.89 (0.47)” | “-8.95 (0.34)” | “-5.72 (0.45)” |
| LS mean (SE) change in HSS7 | “-10.47 (0.40)” | “-6.86 (0.55)” | “-10.47 (0.39)” | “-6.00 (0.53)” |
| LS mean (SE) change in UAS7 | “-20.02 (0.72)” | “-13.79 (0.98)” | “-19.41 (0.70)” | “-11.73 (0.95)” |
| UAS7 ≤6, n (%) | “154 (49.8)” | “38 (24.8)” | “139 (46.8)” | “30 (19.6)” |
| UAS7 = 0, n (%) | “96 (31.1)” | “16 (10.5)” | “83 (27.9)” | “10 (6.5)” |
| Treatment difference versus placebo at Week 12 | REMIX-1 | REMIX-2 |
|---|---|---|
| UAS7 difference in LS mean (SE) | “-6.22 (1.14)” | “-7.68 (1.14)” |
| UAS7 95% CI for difference | “-8.45, -4.00” | “-9.91, -5.46” |
| UAS7 ≤6 treatment difference (95% CI) | “25.44”“16.48, 34.39” | “27.61”“19.14, 36.08” |
| UAS7 = 0 treatment difference (95% CI) | “20.55”“13.35, 27.75” | “21.60”“15.10, 28.10” |
REMIX-1 and REMIX-2: Week 12 UAS7 outcomes and adverse events
“A total of 470 patients in REMIX-1 and 455 in REMIX-2 were randomly assigned to receive either remibrutinib (313 and 300 patients, respectively) or placebo (157 and 155 patients, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The remibrutinib group had a significantly greater decrease in the UAS7 at week 12 than the placebo group (least-squares mean [±SE] change, -20.0±0.7 vs. -13.8±1.0 [P<0.001] in REMIX-1 and -19.4±0.7 vs. -11.7±0.9 [P<0.001] in REMIX-2), which appeared to be sustained through week 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, significantly more patients in the remibrutinib group than in the placebo group had a UAS7 of 6 or lower (REMIX-1, 49.8% vs. 24.8% [P<0.001]; REMIX-2, 46.8% vs. 19.6% [P<0.001]) and a UAS7 of 0 (REMIX-1, 31.1% vs. 10.5% [P<0.001]; REMIX-2, 27.9% vs. 6.5% [P<0.001]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentages of patients with any adverse event and with serious adverse events were similar in the remibrutinib group and the placebo group, although a higher percentage of patients in the remibrutinib group than in the placebo group had petechiae (3.8% vs. 0.3% in the combined groups).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Funded by Novartis Pharmaceuticals;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
REMIX-1 and REMIX-2: Week 52 efficacy and safety
“Patients were randomized 2:1 to receive oral remibrutinib 25 mg twice daily or placebo during a 24-week double-blind placebo-controlled period, followed by a 28-week open-label treatment period (up to 52 weeks).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 52, patients randomized to remibrutinib showed sustained improvements in change from baseline in weekly Urticaria Activity Score (mean [95% confidence interval], REMIX-1: -23.22 [-24.78, -21.66]; REMIX-2: -22.98 [-24.51, -21.44]), with similar responses observed in patients who transitioned from placebo to remibrutinib at week 24 (observed as early as 1 week after transitioning).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Exposure-adjusted incidence rates of adverse events, serious adverse events, and adverse events leading to discontinuation with 52-week remibrutinib treatment remained equivalent to those in the 24-week analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled REMIX-1 and REMIX-2: disease control, sleep, and quality of life through Week 52
“To evaluate the impact of remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor, on disease control, sleep, and QoL in CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) were phase 3, double-blind, placebo-controlled studies in adults with CSU who remained symptomatic despite receiving second-generation H1-antihistamines.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled analysis included 606 and 306 patients receiving remibrutinib and placebo, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Within 1 week of starting remibrutinib, greater improvements in mean (SD) change from baseline (CFB) compared with placebo were noted in urticaria activity (CFB-Urticaria Activity Score: -11.8 [9.9] and -3.6 [7.6]) and sleep (CFB-Sleep Interference Score: -4.9 [4.9] and -1.9 [4.1]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across assessments, responses were sustained through week 52 with remibrutinib, and comparable improvements were observed in those who transitioned to remibrutinib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remibrutinib: bleeding risk, live vaccines, and adverse reactions in the prescribing information
Pooled REMIX-1 and REMIX-2 safety: bleeding, infections, cytopenia, and hepatic disorders
“This was a pooled analysis of REMIX-1 and REMIX-2 consisting of a 24-week, randomized, double-blind, placebo-controlled period, followed by a 28-week open-label treatment period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“AE frequencies and risk differences (95% CI) for remibrutinib (n = 606) versus placebo (n = 306) were as follows: any AE 64.9% versus 64.7%, difference 0.1% (-6.4% to 6.7%); bleeding (including laboratory abnormalities) 10.6% versus 5.2%, difference 5.3% (1.6% to 8.7%); infections 33.5% versus 34.3%, difference -0.8% (-7.4% to 5.6%); cytopenia AEs 3.6% versus 2.0%, difference 1.7% (-0.7% to 3.8%); hepatic disorders 3.3% versus 4.9%, difference -1.6% (-4.6% to 1.1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Imbalance in bleeding was due to petechia and similar mucocutaneous events (predominantly mild, none severe) occurring in 9.1% of patients on remibrutinib versus 2.0% of patients on placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Findings during the entire study period were consistent with those in the controlled period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remibrutinib: drug interactions and hepatic impairment in the prescribing information
International guideline: remibrutinib suggested as add-on after high-dose H1-antihistamines
“We suggest using remibrutinib” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“as add‐on treatment for patients with CSU unresponsive to high doses of 2nd generation H1‐antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of remibrutinib can be considered in all patients with CSU and especially in patients who do not respond to both high‐dose antihistamine and omalizumab treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“25 mg twice daily will most likely be recommended as the treatment dose” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rilzabrutinib: RILECSU phase 2 Week 12 results in antihistamine-refractory CSU
“What is the efficacy and risk profile of rilzabrutinib, an oral reversible covalent Bruton tyrosine kinase inhibitor, in adults with antihistamine-refractory chronic spontaneous urticaria (CSU)?” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Rilzabrutinib Efficacy and Safety in CSU (RILECSU) randomized clinical trial was a 52-week phase 2 study comprising a 12-week, double-blind, placebo-controlled, dose-ranging period, followed by a 40-week open-label extension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomized 1:1:1:1 to rilzabrutinib, 400 mg, once every evening (400 mg/d), twice per day (800 mg/d), 3 times per day (1200 mg/d), or matching placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis population included only the 143 omalizumab-naive patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, −9.21 vs −5.77; difference, −3.44 [95% CI, −6.25 to −0.62]; P = .02) and UAS7 (LS mean, −16.89 vs −10.14; difference, −6.75 [95% CI, −12.23 to −1.26]; P = .02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further research is needed to determine long-term efficacy and potential harms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rilzabrutinib adverse events: diarrhea, nausea, and headache
“adverse events occurring at a higher frequency with rilzabrutinib vs placebo included diarrhea, nausea, and headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent treatment-emergent AEs with rilzabrutinib, 800 mg/d, and rilzabrutinib, 1200 mg/d, were diarrhea and nausea, with most events reported as mild, and none reported as severe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Calcineurin inhibitors
International guideline: ciclosporin for CSU unresponsive to licensed treatments, off-label
“Patients with CSU who do not show sufficient benefit from treatment with H1‐antihistamines, especially if they are also unresponsive to omalizumab, can alternatively be treated with ciclosporin 3–5 mg/kg per day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin is off‐label for urticaria and is recommended only for patients with severe disease refractory to any other licensed treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest using ciclosporin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“currently not licensed for CU” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International guideline: ciclosporin adverse effects, embryotoxicity, and comparison with long-term corticosteroids
“but this drug cannot be recommended as standard treatment due to a higher incidence of adverse effects, especially with long‐term use” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, ciclosporin has a far better risk/benefit ratio compared to long‐term use of steroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ciclosporin, although not teratogenic, is embryotoxic in animal models and is associated with preterm delivery and low birth weight in human infants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin can be especially effective in selected patients with CSUaiTIIb with low total IgE levels and other markers of autoimmunity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Draft joint task force guideline: calcineurin inhibitor after advanced systemic therapy
Cyclosporine meta-analysis: response rates and dose-dependent adverse events
“Eighteen studies (909 participants) including 2 randomized controlled trials were included, with 125, 363, and 266 patients with CSU receiving very low (<2 mg/kg/d), low (from 2 to< 4 mg/kg/d), and moderate (4-5 mg/kg/d) doses of CsA, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall response rate to CsA treatment with low to moderate doses at 4, 8, and 12 weeks was 54%, 66%, and 73%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients treated with very low, low, and moderate doses of CsA, 6%, 23%, and 57% experienced 1 or more adverse event, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Given the limited number and quality of studies, our results should be interpreted with caution.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that the appropriate dosage of CsA for CSU may range from 1 to 5 mg/kg/d, and 3 mg/kg/d is a reasonable starting dose for most patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis for the joint task force guideline: cyclosporine effective but among the most harmful
Predictors of response to cyclosporine: systematic review
“This study aimed to systemically review literature relating to factors that could potentially predict a favorable response to cyclosporine A (CsA) treatment for chronic spontaneous urticaria (CSU).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 13 studies (404 patients with CSU and 200 healthy patients) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since most positive results were from non-RCT articles and some data were still inconsistent, this systematic review identified no reliable practical biomarker for predicting CsA treatment response in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type IIb autoimmune CSU: good response to cyclosporine
Systemic corticosteroids for acute exacerbations
International guideline: short rescue course for acute exacerbations and against long-term use
“We recommend against the long‐term use of systemic glucocorticosteroids or depot preparations in CU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest considering a short course of rescue systemic glucocorticosteroids in patients with an acute exacerbation of CU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For acute urticaria and acute exacerbations of CSU, a short course of oral corticosteroids, that is, treatment of a maximum of up to 10 days, may, however, be helpful to reduce disease duration/activity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, well‐designed randomized clinical trials are lacking.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International guideline: prednisone-equivalent dose, licensing, and use in children
“If systemic corticosteroids are used, doses between 20–50 mg/day of prednisone equivalent are needed (dose is appropriate for adults and not children).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because such high doses will have side effects over the long term, we strongly recommend against the prolonged use of corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Depending on the country it must be noted that steroids are also not licensed for CU” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a short course of corticosteroids as advised in the algorithm should be used only as a very restricted measure in children.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroid use, adverse events, and health care resource use in a Novartis-funded US claims study
“This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study and article publication, including the journal’s Rapid Service Fee, was funded by Novartis Pharmaceuticals Corporation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroids as the most prescribed treatment in a US claims cohort with diagnosed CSU
“Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Corticosteroids were the most prescribed treatment during follow-up among the 166,195 patients prescribed at least 1 treatment (94.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: antihistamine-refractory and uncontrolled disease
- Updosing: in a meta-analysis, 63·2% (95% CI 57 to 69·6) of participants with CSU who did not respond to a standard antihistamine dose responded to updosing; the authors state that study weakness and heterogeneity made a final conclusion difficult. A dose-response network meta-analysis of 211 trials (22,187 participants) suggested that there may be diminishing additional benefit beyond standard dosing (8 more per 100 participants improving by a minimal important difference with a double dose and 16 more with a quadruple dose).
- Real-world control: in the AWARE study, sponsored by the manufacturer of omalizumab, uncontrolled CSU (UCT below 12) at Month 24 was reported in 23.2% (26 of 112) of participants on non-sedating H1-antihistamines, 41.9% (44 of 105) on updosed non-sedating H1-antihistamines, and 27.1% (78 of 288) on omalizumab.
- US claims: proxy events for uncontrolled CSU (prescriptions for corticosteroids, biologics, or immunosuppressants, or CSU-related inpatient, emergency department, or urgent care visits) occurred in 59.1% of adults with diagnosed CSU, and, excluding over-the-counter medication and antihistamines, corticosteroids were the most prescribed treatment after diagnosis (78.3% of 200,298 adults; 68.2% systemic).
Summary: response and nonresponse to omalizumab
- Week 12 response: in CSU Trial 1 of the label, UAS7=0 was reported in 36% with omalizumab 300 mg and 9% with placebo. In participants symptomatic despite H1-antihistamines at up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists, UAS7 of 6 or less was reached by 132 (52.4%) with omalizumab 300 mg and 10 (12.0%) with placebo, and UAS7 = 0 by 85 (33.7%) and 4 (4.8%).
- Insufficient response: the international guideline states that omalizumab at higher doses, shorter intervals, or both is off-label. Nonrandomized data (n = 149) suggest that 69% (95% CI 59% to 78%) of patients refractory to standard-dose omalizumab may respond with higher doses or more frequent administration. Type IIb autoimmune CSU is characterized by poor response to antihistamines and to omalizumab.
- Persistence: in a meta-analysis of 8 observational studies (4516 participants), median omalizumab drug survival was 3.1 years, 7-year survival was 30% in CSU alone, and autoimmune comorbidity was associated with discontinuation for lack of efficacy (HR 2.03; 95% CI 1.20 to 3.41).
- Safety: the label estimates anaphylaxis in at least 0.2% of patients from postmarketing reports and directs that omalizumab be initiated only in a healthcare setting equipped to manage anaphylaxis.
Summary: response and nonresponse to dupilumab and remibrutinib
- Dupilumab: in anti-IgE-naive participants, UAS7 = 0 at Week 24 was reported in 22 (32.4%) with dupilumab and 9 (13.2%) with placebo in CUPID Study A, and in 22 (30.1%) and 13 (17.3%) in Study C. CUPID Study B, in 108 participants who were inadequate responders to or intolerant of anti-IgE treatment, did not meet its primary endpoint (ISS7 at Week 24). The international guideline states that dupilumab efficacy is likely to be less pronounced than that of omalizumab, and a network meta-analysis states that its impact on quality of life is uncertain and that no dupilumab trial addressed angioedema activity.
- Remibrutinib: at Week 12, UAS7 = 0 was reported in 96 (31.1%) with remibrutinib and 16 (10.5%) with placebo in REMIX-1, and in 83 (27.9%) and 10 (6.5%) in REMIX-2. The label reports bleeding in 9% of patients treated with remibrutinib and 2% with placebo over the 24-week controlled period, requires interruption for 3 to 7 days before and after surgery, and advises avoiding use with strong or moderate CYP3A4 inhibitors or inducers and in hepatic impairment (Child-Pugh A, B, and C); safety and effectiveness have not been established in pediatric patients. The network meta-analysis commissioned for the US guideline states that the safety profile of remibrutinib is less certain.
Summary: ciclosporin and systemic corticosteroid harms, cost, and preferences
- Ciclosporin is off-label for urticaria and the international guideline recommends it only for severe disease refractory to licensed treatments. In a meta-analysis of 18 studies (909 participants), response to low to moderate doses was 54%, 66%, and 73% at 4, 8, and 12 weeks, and 6%, 23%, and 57% of participants on very low, low, and moderate doses had 1 or more adverse events. The guideline states that ciclosporin is embryotoxic in animal models and associated with preterm delivery and low birth weight.
- The international guideline recommends against long-term systemic corticosteroids and suggests a rescue course of up to 10 days for acute exacerbations. In US claims, the 10 most common adverse events after systemic corticosteroid initiation, including hypertension, lipid disorders, diabetes, and cataracts, occurred in higher proportions of corticosteroid users than non-users, and the proportion with adverse events generally increased with longer use.
- The international guideline acknowledges that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost and that ciclosporin is restricted by its safety profile. Across 18 studies of patient values and preferences (28,497 participants), oral or topical treatments were favored over injections and infusions were least favored (moderate certainty).
Response to updosed antihistamines in non-responders to standard doses: meta-analysis
“We did not find significant differences in response rates or number of weals in those patients who received a standard dosage vs. a high dosage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of nonrespondent patients with CSU who responded to antihistamine updosing was 63·2% (95% CI 57-69·6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the relative weakness of the studies and the significant heterogeneity among them made it difficult to reach a final conclusion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled CSU at Month 24 on antihistamines and on omalizumab: AWARE, sponsored by the manufacturer of omalizumab
“AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients with uncontrolled CSU (UCT score <12) dropped from 78% (n/N = 1641/2104) at baseline to 28.7% (n/N = 269/936) after two years of participation in the AWARE study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Further studies are needed to understand the differences between guideline recommendations and reported management.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled CSU among treated participants in a US claims cohort
“Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Proxy events representing uncontrolled CSU (any record of prescriptions for corticosteroids, biologics, or immunosuppressants [excluding all antihistamines and over-the-counter medication] or any CSU-related inpatient admissions or emergency department or urgent care visits) were used to identify patients with uncontrolled CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Proxy events were observed in 59.1% of the patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of patients with CSU who were prescribed treatment, more than 50% experienced uncontrolled CSU, which was associated with increased HCRU and health care costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insufficient response to licensed-dose omalizumab and off-label updosing
“Patients with urticaria who do not show sufficient benefit from treatment with omalizumab at the licensed dose of 300 mg every 4 weeks can be treated with omalizumab at higher doses, shorter intervals, or both.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients need to be informed that omalizumab updosing is off‐label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type IIb autoimmune CSU: poor response to antihistamines and omalizumab
Dupilumab in participants symptomatic despite anti-IgE treatment: CUPID Study B did not meet the primary endpoint
Omalizumab: anaphylaxis boxed warning and initiation in a healthcare setting
Remibrutinib: bleeding and interruption around surgery
Cost and safety restrictions on advanced therapies and ciclosporin in the international guideline
“alternative treatments are needed for the remaining unresponsive patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost, and that ciclosporin restricted due to its safety profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient values and preferences: oral treatments favored over injections
“The search resulted in 18 studies addressing the values and preferences among 28 497 participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moderate certainty evidence showed that patients were likely to place a high value on rapid improvement (eg, 2 days to 2 weeks) of disease signs and symptoms, long-term effectiveness, and treatments that were easy to prepare, use, and self-manage-oral or topical treatments were favored over injections, with the least favored being infusions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab drug survival and discontinuation for lack of efficacy
“The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
The 2026 international guideline sequences treatment as a standard-dose second-generation H1-antihistamine first line, updosing up to 4-fold second line, then add-on omalizumab (recommended), dupilumab, or remibrutinib (both suggested) for CSU unresponsive to high-dose antihistamines, and off-label ciclosporin for CU unresponsive to licensed treatments. The guideline states that remibrutinib can be considered especially in patients who do not respond to both high-dose antihistamines and omalizumab, acknowledges cost restrictions on the three advanced therapies, and notes that treatments under development aim, among other approaches, to reduce mast cell numbers. A US Joint Task Force guideline that addresses the sequencing of conventional and advanced therapies was in draft for member review in 2026; the network meta-analysis commissioned for it rated standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib among the most effective with high certainty. In a primary care pathway, patients who remain symptomatic and adherent after up to four times the standard antihistamine dose should be referred for specialist evaluation, where total IgE and IgG-anti-TPO may be tested to indicate the likelihood of response to omalizumab. The barzolvolimab phase 3 trials, which study adults with CSU who remain symptomatic despite H1 antihistamine treatment, enrolled 1,939 participants, including advanced therapy-experienced or refractory participants, and are designed to detect a difference in an omalizumab-refractory subpopulation. The manufacturer describes barzolvolimab as positioned “as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.” It is supplied for the trials in 1 mL pre-filled syringes for subcutaneous injection, which the manufacturer states allows potential self-administration at home.
International guideline update: development method
“This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proposed population: adults symptomatic despite H1 antihistamine treatment
Manufacturer positioning: first-line therapy in severe disease or angioedema and second-line advanced therapy
Enrollment of advanced therapy-experienced participants and design for an omalizumab-refractory subpopulation
Care setting: subcutaneous pre-filled syringe with potential self-administration at home
International guideline treatment algorithm: antihistamines, then omalizumab, dupilumab, or remibrutinib, then ciclosporin
“We recommend a 2nd generation H1-antihistamine as first-line treatment for all types of urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend updosing of a 2nd generation H1-antihistamine up to 4-fold in patients with chronic urticaria unresponsive to a standard-dosed 2nd generation H1-antihistamines as second-line treatment before other treatments are considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend adding on omalizumab* for the treatment of patients with CU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest using dupilumab* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest using remibrutinib* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest using ciclosporin* for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International guideline: positioning of remibrutinib and ciclosporin after omalizumab
“The use of remibrutinib can be considered in all patients with CSU and especially in patients who do not respond to both high-dose antihistamine and omalizumab treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin is off-label for urticaria and is recommended only for patients with severe disease refractory to any other licensed treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International guideline: cost and safety restrictions on advanced therapies
“It is strongly recommended to stick to the treatment algorithm, but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost, and that ciclosporin restricted due to its safety profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International guideline: treatments under development that reduce mast cell numbers
Specialist care: biomarker testing and referral for comorbidities
“In patients under specialist care, additional tests, such as total IgE and IgG-anti-TPO may be performed, as they indicate the likelihood of response to omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, any findings from the patient's medical history, physical examination, or basic testing that suggest the presence of a comorbidity or consequence of CSU should prompt further investigations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These may include screening for specific diseases by questionnaires, provocation tests, further laboratory tests, or a referral to a specialist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary care pathway: specialist referral after up to fourfold antihistamine dosing
“Urticaria is a common condition presenting both as acute and chronic disease within primary care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If symptoms are controlled on any dose of a long-acting non-sedating antihistamine up to a maximum of four times the standard dose or if the symptoms have spontaneously remitted, no referral is necessary.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The corollary of this is that all patients who remain symptomatic and who have been adherent to medication, should be referred for specialist evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Draft US joint task force guideline: member review and scope, including sequencing of advanced therapies
Network meta-analysis commissioned for the draft US guideline: comparative effectiveness of systemic treatments
Heterogeneity of treatment effect
Barzolvolimab phase 2: efficacy at Week 12 and Week 52 by baseline total IgE
Barzolvolimab phase 2: Week 12 response with and without prior omalizumab
Barzolvolimab phase 3: complete response (UAS7=0) at Week 12, overall and in omalizumab-refractory participants
| Population and arm, Week 12 | EMBARQ-CSU1 | EMBARQ-CSU2 |
|---|---|---|
| Overall, placebo | “9.3%” | “12.6%” |
| Overall, 150 mg Q4W | “42.4% (p<.00001)” | “45.7% (p<.00001)” |
| Overall, 300 mg Q8W | “42.1% (p<.00001)” | “44.0% (p<.00001)” |
| Omalizumab-refractory, placebo | “9.3%” | “15.1%” |
| Omalizumab-refractory, 150 mg Q4W | “55.3% (p<.00001)” | “41.7% (p=.0089)” |
| Omalizumab-refractory, 300 mg Q8W | “44.3% (p=.00017)” | “46.4% (p=.0036)” |
Barzolvolimab phase 2: efficacy by baseline serum tryptase
International guideline: biomarkers of response to omalizumab, dupilumab, ciclosporin, and antihistamines
“In patients under specialist care, additional tests, such as total IgE and IgG-anti-TPO may be performed, as they indicate the likelihood of response to omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the established statistical association, the diagnostic performance and predictive accuracy of these tests remains limited” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Available data shows efficacy regardless of low baseline IgE levels for dupilumab, which is different compared to omalizumab where very low IgE values are often a reason for insufficient response” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin can be especially effective in selected patients with CSUaiTIIb with low total IgE levels and other markers of autoimmunity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, the presence of concomitant CIndU, high disease activity, elevated CRP and/or the presence of angioedema are indicative for a prolonged duration of CSU and suboptimal response to antihistamine treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of predictors of response to antihistamines, omalizumab, and cyclosporine
“A systematic search was performed by two independent researchers using the MEDLINE/PubMed database with specific keywords and 73 studies included in the review.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“High disease activity, high levels of C-reactive protein and D-dimer are robust predictors for a poor or no response to sgAHs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Poor or no response to omalizumab is robustly predicted by low serum levels of total IgE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A good response to cyclosporine is robustly predicted by a positive basophil histamine release assay, whereas low total IgE is an emerging predictor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab: response by baseline total IgE and its change after 4 weeks
“Total IgE levels were measured before treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nonresponse to omalizumab was best predicted by patients' w4IgE/bIgE ratios, significantly better than by bIgE levels (P = .016).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Type IIb autoimmune endotype: low total IgE and poor response to antihistamines and omalizumab
Dupilumab: response by baseline total IgE in omalizumab-naive participants
“Dupilumab treatment improved ISS7, UAS7, and HSS7 over 12 and 24 weeks, regardless of baseline serum IgE level (interaction p ≥ 0.59 for all treatment by subgroup comparisons)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the current analysis, baseline total IgE had no predictive value as a dupilumab treatment response biomarker in CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dupilumab is an effective treatment in H1-antihistamine (H1-AH)-resistant, omalizumab-naïve patients with CSU, regardless of their baseline serum total IgE levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dupilumab: label statements on baseline IgE and on anti-IgE inadequate responders
Remibrutinib and dupilumab by prior biologic or omalizumab exposure
“Dupilumab, a monoclonal antibody that blocks IL-4Ra, significantly reduced urticaria activity in omalizumab-naive patients and showed smaller effects in patients who were omalizumab-intolerant/incomplete responders” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remibrutinib, a Bruton's tyrosine kinase inhibitor, has shown efficacy in reducing disease symptoms in patients remaining symptomatic despite treatment with sgH1-AH in clinical trials, without a notable drop in efficacy in biologic-experienced patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cyclosporine: candidate predictors of response, systematic review
“Our systematic review showed that positive autologous serum skin test results, positive baseline basophil histamine release assays, positive baseline basophil activation test responses, elevated baseline plasma D-dimer levels, elevated baseline serum interleukin (IL)-2, IL-5, and tumor necrosis factor-alpha (TNF-α) levels, and low baseline serum IgE levels might assist in predicting favorable CsA responses in CSU patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since most positive results were from non-RCT articles and some data were still inconsistent, this systematic review identified no reliable practical biomarker for predicting CsA treatment response in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparative network meta-analysis: consistency across age groups and baseline severity
Sex: poorer urticaria control in women across treatment categories, CURE registry
“Specifically, a higher number of females had UCT < 12 compared to males when treated with standard-dose second-generation anti-histamines (sgAH; 70.5% vs. 66.9%, p = 0.02), high-dose sgAH (76.5% vs. 73.9%, p = 0.02), omalizumab (53% vs. 44.5%, p = 0.03) and cyclosporine (81% vs. 71.4%, p = 0.02; Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We analysed Chronic Urticaria Registry (CURE) data, an international real-world registry for patients with chronic urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Patient-reported outcome measures at every visit
“Patients should be assessed for disease activity, impact, and control at all visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The UAS7, calculated as the sum of daily scores over 7 consecutive days, should be routinely used to monitor disease activity and treatment response in patients with CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to highlight that patients need good counseling regarding continuous treatment and using PROMs, especially about using the UAS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stepping treatment up or down: assess, act and adjust, and reassess
“Treatment should follow the basic principles of treating as much as needed and as little as possible, taking into consideration that the activity of the disease may vary” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This implies stepping up or stepping down in the treatment algorithm according to the course of disease following the principle assess, act & adjust, and reassess” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In order to constantly ensure the right level of treatment, patients need to be seen at regular intervals and adjustments are recommended based on the level of symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For a stepdown, different options exist but costs are especially relevant for choosing which step to take first.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients who are in the range of UCT 12–15, therefore a step up might also be required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab interval prolongation after 3 months of complete control
“After 3 months of complete control, the interval can be prolonged until long as first wheals reappear, as there is no tachyphylaxis nor have relevant levels of blocking antibodies been described.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“But also, the prolongation of the interval is strictly off label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab step-down: relapse after gradual de-escalation versus abrupt discontinuation, meta-analysis
“Random-effects proportion meta-analysis (DerSimonian-Laird logit transformation) determined pooled relapse rates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall pooled post-discontinuation relapse rate was 39.5% (95% CI: 30.1%-49.7%; I2 = 91.5%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gradual de-escalation achieved a significantly lower pooled relapse rate compared with abrupt discontinuation (31.2% [95% CI: 20.3%-44.7%] vs. 48.9% [95% CI: 37.0%-61.0%], Qb = 8.12, df = 1, p = 0.004).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Concomitant angioedema was an independent risk factor for relapse (multivariate OR = 2.399, p = 0.004), whereas gradual de-escalation was protective (multivariate OR = 0.373, p = 0.005).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab cessation: pooled relapse across 41 stopping risk sets and uncertainty about stopping strategies
“Forty-one stopping risk sets (2,643 patients; 1,209 source-reported events) yielded a pooled proportion of 46.6% (95% CI 40.1-53.2%; I2 = 87.7%; prediction interval 16.0-79.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Relapse is common after cessation, but high heterogeneity limits individualized prediction. The evidence cannot establish a causal advantage of any stopping strategy or an immune endotype for recurrence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary care: periodic antihistamine withdrawal to test for remission
“Urticaria is a common condition presenting both as acute and chronic disease within primary care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, when remission is achieved, therapy should be withdrawn every 3–6 months to discover whether natural remission has occurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Barzolvolimab phase 3b extension: observation of controlled disease and retreatment on flare
Treatment escalation in practice: CURE registry
“This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“About one-third (28.6%) of patients clinically eligible for escalation at BL (UCT < 12) did not receive step-up treatment (18.0%) or were even stepped down (10.6%) and remained poorly controlled at FU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many patients with poorly controlled CSU do not receive guideline-recommended treatment escalation and remain symptomatic on their current treatments, which deserves further attention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mobile app symptom monitoring: adherence to CRUSE
“We analysed data from 2085 patients (66,114 days). Median adherence to the CRUSE app was of 22 days (24.4% of 90 days).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our findings suggest that age, male sex, residence in Europe, and the use of monoclonal antibodies are significant factors associated with increased adherence to the CRUSE app.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality-improvement study of guideline-based care: planned steps
“Finally, some physicians are not aware of, or do not adhere to, international guidelines available for the treatment of CSU” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Step 3 (quality improvement): Recommendations to improve quality of care for patients with CSU will be developed, pilot tested, and published.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Treatment goal: continuous complete control and normal quality of life
“The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall aim of the management in urticaria is to achieve complete control of symptoms and maintain effective and safe treatment until the disease is gone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The UCT cutoff value for well-controlled disease is 12 out of 16 possible points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer statement of complete response as the treatment goal
Complete control and complete response rates in practice, CURE registry
“We report real-world data from the global Chronic Urticaria Registry (CURE)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, 9.8%, 17.9%, and 42.3% of patients had UCT = 16, UAS7 = 0, or PhyGA = CR, respectively, which increased at FU1 and FU2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Few patients had CR/CC of their CSU at baseline entry. Disease control strongly related to good sleep and better HRQoL; therefore, it is important to aim for CR in CSU treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complete response after treatment escalation, CURE registry
“This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complete response was defined as UCT = 16 with a ≥ 3-point increase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After treatment escalation from BL to FU, 5.3% (no treatment to licensed-dose sgH1-AH), 6.0% (licensed-dose sgH1-AH to up-dosed sgH1-AH), and 28.4% (any dose sgH1-AH to omalizumab) achieved complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Appropriate treatment escalation improves CSU control, although only about a quarter of patients achieve a complete response, indicating the need for novel treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled disease at Month 24 in antihistamine-refractory CSU, AWARE study sponsored by the manufacturer of omalizumab
“AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world omalizumab complete response rate, meta-analysis supported by Novartis
“In this meta-analysis of 67 published reports on real-world effectiveness, omalizumab therapy was associated with an average 25.6-point improvement in weekly Urticaria Activity Score (vs a 14.9 to 22.1 point improvement reported in clinical trials), a 4.7 point improvement in Urticaria Activity Score, a complete response rate of 72.2%, a partial response rate of 17.8%, and an average adverse event rate of 4.0% (vs 2.9%-8.0% reported in clinical trials).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was supported by Novartis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Barzolvolimab phase 3: complete response (UAS7=0) at Week 12
| Arm, Week 12 | EMBARQ-CSU1 | EMBARQ-CSU2 |
|---|---|---|
| Placebo | “9.3%” | “12.6%” |
| 150 mg Q4W | “42.4% (p<.00001)” | “45.7% (p<.00001)” |
| 300 mg Q8W | “42.1% (p<.00001)” | “44.0% (p<.00001)” |